

## **PART I: General Information**

Updated:

January 11, 2010

**Name:** C. Ronald Kahn

**Office Address:** Joslin Diabetes Center, One Joslin Place, Boston, MA 02215

**Email:** c.ronald.kahn@joslin.harvard.edu

**Phone:** (617) 732-2635                      **FAX:** (617) 732-2487

**Place of Birth:** Louisville, Kentucky

### **Education:**

1964 B.A.      University of Louisville (Chemistry, with highest honors)  
1968 M.D.      University of Louisville School of Medicine (with highest honors)  
1984 M.S.      University of Louisville (Chemistry)  
1984 M.A.      Harvard University (Honorary)  
1984 D.Sc.      University of Louisville (Honoris Causa)  
1990 D.Sc.      Universite de Paris Pierre et Marie Curie (Honoris Causa)  
2000 D.Sc.      University of Geneva (Honoris Causa)  
2008 D.Med.   University of Copenhagen (Honoris Causa)

### **Postdoctoral Training:**

#### Internship/Residencies:

1968-1970    Intern and Resident, Ward Medicine, Barnes Hospital, St. Louis, MO

#### Research Fellowships:

1970-1973    Clinical Associate and Senior Clinical Associate, Clinical Endocrinology  
Branch, National Institutes of Arthritis, Metabolism and Digestive Diseases,  
NIH, Bethesda, MD

### **Licensure and Certification:**

1968            Kentucky State Board of Medical Examiners, No. 15141  
1973            American Board of Internal Medicine, No. 44765  
1973            American Board of Internal Medicine, Subspecialty in  
Endocrinology and Metabolism, No. 44765  
1981            Massachusetts State Medical Registration, No. 48036

### **Academic Appointments:**

- 1980-1981 Adjunct Professor of Genetics, George Washington University, Washington, DC
- 1981-1984 Associate Professor of Medicine, Harvard Medical School, Boston, MA
- 1984- Professor of Medicine, Harvard Medical School, Boston, MA
- 1986- Mary K. Iacocca Professor of Medicine, Harvard Medical School, Boston, MA

**Hospital or Affiliated Institution Appointments:**

- 1972-1981 Admitting & Attending physician, National Institutes of Health, Clinical Center
- 1981-1991 Physician, Brigham and Women's Hospital, Boston, MA
- 1981-1992 Chief, Division of Diabetes and Metabolism, Department of Medicine, Brigham and Women's Hospital, Boston, MA
- 1985- Senior Staff, Joslin Clinic, Joslin Diabetes Center, Boston, MA
- 1981-1985 Associate Staff, Endocrinology/Internal Medicine, New England Deaconess Hospital, Boston, MA
- 1986-1995 Active Staff, Department of Medicine, Internal Medicine and Endocrinology, New England Deaconess Hospital, Boston, MA
- 1986-1992 Senior Physician, Brigham and Women's Hospital, Boston, MA
- 1993- Senior Consultant in Diabetes and Metabolism, Brigham and Women's Hospital, Boston, MA
- 1995- Active Staff, Department of Medicine, Beth Israel Deaconess Hospital, Boston, MA

**Other Professional Positions and Major Visiting Appointments:**

- 1973-1978 Senior Investigator, Diabetes Branch, National Institute of Arthritis, Metabolism and Digestive Diseases, NIH, Bethesda, MD
- 1979-1980 Visiting Scientist, Centre de Moleculaire, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France
- 1979-1981 Chief, Section on Cellular and Molecular Physiology, Diabetes Branch, National Institute of Arthritis, Metabolism, and Digestive Disease, NIH, Bethesda, MD
- 1981 Clinical Associate Professor of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD
- 1985 Overseas Visiting Professor, Royal Melbourne Hospital, Melbourne, Australia
- 1985 Visiting Professor, Royal Postgraduate Hospital, London, England
- 1985 Rosemary Sarver Visiting Professor in Endocrinology and Metabolism, The Hospital of the Good Samaritan, Los Angeles, CA
- 1990 Roerig Visiting Professorship in Diabetes, University of Colorado Health Sciences Center, Denver, CO
- 1990-1991 Visiting Scientist, Department of Cellular and Molecular Biology, Dana Farber Cancer Institute, Boston, MA
- 1998-Pres Visiting Research Scientist, Brandeis University, Waltham, MA
- 2005 Honorary Director and Professor of the Diabetes Center at Peking University, Beijing, China
- 2007 International Visiting Fellow, Garvan Institute, Sydney, Australia
- 2007 International Advisory Board, PhD School of Molecular Metabolism, University of Southern Denmark

**Major Administrative Responsibilities:**

- 1981-2000 Director, Elliott P. Joslin Research Laboratory, Joslin Diabetes Center
- 1981-2002 Head Section on Cellular and Molecular Physiology, Joslin Diabetes Center
- 1997-2000 Executive Vice President and Director, Joslin Diabetes Center
- 2000-2007 President and Director, Joslin Diabetes Center
- 2000-2003 Member, Board of Directors, Care Group, Health Care System
- 2000-2007 Member, Board of Directors, Medical Academic and Scientific Community Organization (MASCO)
- 2002-2008 Head Section of Obesity and Hormone Action Research, Joslin Diabetes Center
- 2007- Vice Chair, Board of Trustees, Joslin Diabetes Center
- 2008- Head Section of Molecular Physiology and Hormone Action, Joslin Diabetes Center

**Major Committee Assignments:****Medical School:**

- 1985-1988 Member, Committee on Promotions and Appointments, Harvard Medical School
- 1987-1990 Member, Standing Committee on Faculty Fellowships, Harvard Medical School
- 1989-1994 Member, Appeals Board, Student Promotion Board, Faculty of Medicine, Harvard Medical School
- 1997-1998 Member, Faculty Council, Harvard Medical School
- 2005- Member, Glenn Laboratories on Aging Research, Scientific Advisory Board

**Affiliated Institutions:**

- 1996- Member, Scientific Advisory Committee, Boston Obesity Center, New England Medical Center, Boston, MA

**Regional, National and International:**

- 1977-1981 Quality Assurance Committee, National Institute of Health
- 1978 Co-Chairman, Organizing Committee, Fogarty International Conference on Hormones and Cancer, Bethesda, MD, (March 29-31)
- 1978-1980 Postgraduate Committee, Endocrine Society
- 1979-1982 Medical Science Advisory Board, Juvenile Diabetes Foundation
- 1981-1984 Nominating Committee, Endocrine Society
- 1982-1985 Research Committee, American Diabetes Association
- 1983 Vice Chairman, Organizing Committee, Hormone Action, Gordon Conference, Meriden, NH (August 7-12)
- 1983 Scientific Committee, Second International Symposium on Insulin Receptors and Insulin Action, Rome, Italy (August 31-September 3)
- 1983-1986 Medical Science Advisory Committee, Juvenile Diabetes Foundation
- 1984 Co-Chairman, Organizing Committee, UCLA Symposia on Molecular and Cellular Biology Membrane Receptors and Cellular Recognition, Park City, UT (March 25-30)

- 1984 Chairman, Organizing Committee, Gordon Conference on Hormone Action, Meriden, NH (August 5-10)
- 1985 Scientific Committee, Third International Symposium on Insulin Receptors and Insulin Action
- 1985 Chairman, Organizing Committee, Gordon Conference on Hormone Action, Meriden, NH (August 4-9)
- 1985 Organizing Committee, JDFI World Conference on Diabetes Research - Current Status and Future Directions, Monaco (November 4-6)
- 1986 Organizing Committee, Immunology of Diabetes - Immunity to Insulin and the Insulin Receptor, Edmonton, Canada (June 26-28)
- 1987-1988 Countdown Editorial Advisory Board, Juvenile Diabetes Foundation
- 1988 Chairman, Organizing Committee, Insulin and The Cell Membrane, Smolenine Castle, Czechoslovakia (June 27-30)
- 1988 Chairman, Organizing Committee, The Action of Insulin and Related Growth Factors in Diabetes Mellitus, Joslin Diabetes Center's 90th Anniversary Symposium, Boston, MA (October 10-13)
- 1988-1990 Medical Science Advisory Committee, Juvenile Diabetes Foundation
- 1990-1993 Council Member, Endocrine Society
- 1991 Organizing Committee, Keystone Symposia on Diabetes and Insulin Action, Park City, UT (January 18-24)
- 1992 Organizing Committee, FASEB Summer Conference on Receptors and Signal Transduction, Copper Mountain, CO (July 12-17)
- 1992-2000 Central Committee of International Society of Endocrinology
- 1992-1996 National Institutes of Health Reviewer's Reserve
- 1993-1994 Chair, Council on Molecular, Cellular and Biochemical Aspects of Diabetes, American Diabetes Association
- 1996 Organizing Committee, VI<sup>th</sup> International Symposium on Insulin Receptors and Insulin Action, Copenhagen, Denmark (May 6-10)
- 1996 Organizing Committee, 75<sup>th</sup> Anniversary of the Discovery of Insulin, Toronto, Canada (October 6-9)
- 1997 Member, Cardiovascular Advisory Board, Monsanto/Searle
- 1997 Organizing Committee, 16th International Diabetes Federation Congress, Helsinki, Finland (July 20-25)
- 1997-2000 Member, International Endocrine Society Steering Committee
- 1998 Co-Chair, Organizing Committee, Diabetes Mellitus: From Patients to Genes and Back, A symposium on the 100<sup>th</sup> Anniversary of the Joslin Diabetes Center, Boston, MA (October 21-23)
- 1998- Member, External Advisory Committee, JDFI Program Project, Mount Sinai School of Medicine, New York, NY
- 1998- Advisory Board, NRSA Training Grant, State University New York at Stony Brook
- 2000 Co-Chair, Organizer of Keystone Symposium on Diabetes, Taos, NM (February 16-22)
- 2003 Co-Chair, Proteomics in Diabetes Meeting, Bethesda, MD (April 24-25)
- 2003 Fellow, American Academy of Microbiology, Recognizing Scientific Excellence
- 2004-2006- Member, External Scientific Advisory Board, University of Geneva Selection Committee, Luft Prize, Karolinska Institute, Stockholm, Sweden
- 2008 Co-Chair, NIDDK Workshop on Adipose Development, Bethesda, MD

2008- Member, Scientific Advisory Board, Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD)

**Assignments on National Commissions:**

1981-1985 National Diabetes Advisory Board  
1982-1985 Co-Chairman, Research Committee, National Diabetes Advisory Board  
1995-1998 Member on the Endocrinology Study Section, Division of Research Grants, National Institutes of Health  
1998-2002 NIDDK Board of Scientific Counselors  
1998 Co-Chair, Workshop on Diabetes Research: Challenges and Opportunities, National Institutes of Health  
1998-1999 Chair, Congressionally-mandated Diabetes Research Working Group (DRWG)  
1998-2002 Member, National Diabetes and Digestive and Kidney Diseases Advisory Council, National Institutes of Health  
2002-2007 Awards Committee, Endocrine Society, Bethesda, Maryland  
2007-2011 Chair, Class IV Medical Sciences, National Academy of Science  
2007-2009 Finance Committee, American Diabetes Association  
2008-2009 NIDDK Diabetes Research Strategic Plan, Chair, Systems Biology Committee  
2010- Research Policy Committee, American Diabetes Association

**Professional Societies:**

1963- Member, Alpha Epsilon Delta  
1964- Member, Phi Kappa Phi  
1965- Member, Alpha Omega Alpha  
1966- Member, Sigma Xi  
1972- Member, American Federation for Clinical Research  
1975- Member, The Endocrine Society  
1976- Member, American Diabetes Association  
1979- Member, American Society for Clinical Investigation  
1982- Member, American Society of Biological Chemistry  
1983- Member, Association of American Physicians  
1986- Member, National Council, American Society of Clinical Investigation  
1987-1988 President-Elect, American Society of Clinical Investigation  
1988-1989 President, American Society of Clinical Investigation  
1991- Member, American Academy of Arts and Sciences  
1994- Fellow, American Association for the Advancement of Science  
1999- Member, National Academy of Science  
1999- Member, Institute of Medicine  
2005- Fellow, American College of Physicians  
2005- Honorary Member, British Society for Endocrinology

**Editorial Boards:**

1977-1980 Journal of Clinical Endocrinology and Metabolism  
1977-1984 Diabetes  
1979-1984 American Journal of Medicine  
1979-1984 Journal of Clinical Investigation

1980-1983 Journal Receptor Research  
 1980-1983 Hormone and Metabolic Research  
 1981-1985 Endocrinology  
 1983-1988 Journal of Biological Chemistry  
 1984-2002 Diabetes and Metabolism Reviews  
 1987-1990 ISI Atlas of Science Editorial Advisory Board  
 1989- Receptor  
 1989-1990 Executive Editor, Trends in Endocrinology and Metabolism  
 1991-1996 Editorial Advisory Council, Journal of Endocrinological Investigation  
 1991-1995 Trends in Endocrinology and Metabolism  
 1992-1996 Consulting Editor, The Journal of Clinical Investigation  
 1992-2002 Journal of Receptor Research  
 1993-1994 Member, Board of Editors, Endocrine  
 1996-2001 Associate Editor, Diabetes  
 1996-1997 Member, Endocrine Reviews Advisory Board  
 1997-2002 Editorial Board, Proceedings of the Association of American Physicians  
 1998-2003 Consulting Editor, Journal of Clinical Investigation  
 1998-2003 Member, Editorial Board, American Journal of Medicine  
 2000-2005 Associate Editor, Endocrine Reviews  
 2001-2006 Editorial Board, American Journal of Physiology  
 2002- Editorial Board, Diabetes/Metabolism Research and Reviews  
 2004- Associate Editor, Cell Metabolism  
 2008- Associate Editor, BMC Endocrine Disorders  
 2008- Editorial Board, Journal of Clinical Endocrinology & Metabolism  
 2009- Editorial Board, Journal of Diabetes Investigation

### **Awards and Honors:**

Undergraduate: Woodcock Honor Society; Phi Lambda Upsilon; Alpha Epsilon Delta;  
 Phi Kappa Phi Honor Society; Graduate with Highest Honors  
 Medical School: Saunder's Award for Biochemistry; Mosby Award; Upjohn Award for  
 Medicine; Alpha Omega Alpha; Sigma Xi; Vice President, Junior Class;  
 President Senior Class; Graduate with Highest Honors  
 Professional:  
 1977 David Rumbough Memorial Award for Scientific Achievement, Juvenile  
 Diabetes Foundation  
 1979 Laurentian Hormone Conference  
 1981 Eli Lilly Award for Research, American Diabetes Association  
 1981 CIBA-Geigy Drew Award for Biochemical Research  
 1982 Mary Jane Kugel Award, Juvenile Diabetes Foundation  
 1983 American Federation for Clinical Research (AFCR) Award for Outstanding  
 Clinical Research Under Age 40  
 1983 Sol Berson Memorial Lectureship, National Institutes of Health  
 1984 Hahnemann Lecture in Pharmacology, University of California, San  
 Francisco  
 1984 Artium Magistrum (Honorary), Harvard University  
 1984 Doctor of Science (Honoris Causa), University of Louisville  
 1984 Rachmiel Levine Lectureship, New York Medical College  
 1985 Carl V. Moore Memorial Lecture, Washington University School of  
 Medicine

1986 Kelly West Lecture, University of Oklahoma School of Medicine  
 1986- Mary K. Iacocca Professor of Medicine, Harvard Medical School  
 1986 Pfizer Biomedical Research Award, Pfizer, Inc., Groton, Connecticut  
 1987 Sixty-Eighth Mellon Lecture, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania  
 1987 Ninth Annual Steve Brody Lectureship in Diabetes, Cedars-Sinai Medical Center, Los Angeles, California  
 1987 Edwin B. Astwood Lecturer, The Endocrine Society  
 1987 McGill Novo Nordisk Lecturer, McGill University, Montreal, Canada  
 1988 Gifford Lectureship, Southwestern Medical Center, Dallas, Texas  
 1988 Cristobal Diaz Award, International Diabetes Federation  
 1989 Otto Brandman Award, American Diabetes Association New Jersey Affiliate  
 1989 Elliott P. Joslin Medal, American Diabetes Association, Massachusetts Affiliate  
 1990 Doctor of Science (Honoris Causa), Universite de Paris Pierre et Marie Curie, Paris, France  
 1990 Top 100 Most-Cited Scientists for 1973-1984 and 1981-1988, The Scientist, March 19 and October 1, 1990  
 1991- Fellow, American Academy of Arts and Sciences  
 1993- Alumni Fellow, University of Louisville  
 1993 Banting Medal for Distinguished Scientific Achievement, American Diabetes Association  
 1994 Edwin Krebs Lecture, University of Washington  
 1994 Pincus Taft Lecturer in Clinical Endocrinology, Australian Endocrine Society  
 1995 Fellow, American Association for the Advancement of Science  
 1995 Kroc Lecturer, University of California, Irvine  
 1995 Bates Lecturer, State University of New York, Syracuse  
 1996 Invited Lecturer, Symposium in Honor of the 100<sup>th</sup> Birthday of Carl Cori and Gerty Cori, Harvard Medical School, Boston, MA  
 1997 Distinguished Scientist Award, Clinical Ligand Assay Society  
 1997 Solomon Berson Distinguished Lecture, American Physiological Society  
 1998 Albert Renold Award, American Diabetes Association  
 1998 Lewis Memorial Lecture, Mount Sinai School of Medicine  
 1998 209<sup>th</sup> Eli Lilly Lecturer, Eli Lilly Company  
 1999 Dorothy Hodgkin Award, British Diabetes Association  
 1999- Elected Member, National Academy of Sciences  
 1999- Elected Member, Institutes of Medicine, National Academy of Sciences  
 1999 Nelson Medical Lectureship, University of California Davis School of Medicine  
 2000 Fred Conrad Koch Award for Distinguished Contributions to Endocrinology, Endocrine Society  
 2000 Hamden Award for Medical Research, United Arab Emirates  
 2001 Lawson Wilkins Lecture, Pediatric Endocrine Society and International Pediatric Endocrine Society, Toronto, Canada  
 2001 Donald W. Seldin Lecture, American Society of Nephrology and International Society of Nephrology, San Francisco, CA  
 2001 Rolf Luft Award Lecture, Karolinska Institute, Stockholm, Sweden

- 2001 Naomi Berrie Award for Outstanding Achievement in Diabetes Research, Columbia University, New York, NY
- 2002 Societa'Italiana Di Diabetologia Mentor Award, Italy
- 2002 Steven C. Beering Award for Advancement of Biomedical Science
- 2002 J. Allyn Taylor International Prize in Medicine for Diabetes
- 2002 Jacobeus Prize, Novo-Nordisk Foundation, Lund, Sweden
- 2002 Dean's Distinguished Lecture, University of Colorado School of Medicine
- 2002 Fellow American Academy of Microbiology
- 2002 Fast Breaking Paper in the field of Multidisciplinary as determined by the Thompson-ISI Web of Science database
- 2003 Gordon Wilson Lecture, Transactions of the American Clinical and Climatological Association
- 2003 Stapleton Lecture, University of Colorado School of Medicine
- 2004 9<sup>th</sup> Annual Dundee Signaling Lecture, Scotland
- 2004 Claude Bernard Medal awarded by the European Association for the Study of Diabetes (EASD), Munich, Germany
- 2004 Bristol Myers Squibb Award for Distinguished Achievement in Metabolic Research
- 2005 Dale Medal Lecture, British Society for Endocrinology
- 2005 Honorary Director and Professor of the Diabetes Center of Peking University, Beijing, China
- 2005 Dean's Lecture, Mount Sinai School of Medicine, New York, NY
- 2006 Heskett Lecture, Northwestern University Feinberg School of Medicine
- 2006 Honorary Member, British Society for Endocrinology
- 2006 Banting Memorial Lecture, British Diabetic Association, Birmingham, UK
- 2006 Baxter Lecture, Yale University School of Medicine
- 2006 Best Doctors in America and Best Doctors in Boston for 2005-2006
- 2007 Best Doctors in American 2006-2007
- 2007 International Visiting Fellow, Garvan Institute, Sydney, Australia
- 2008 Mary Shorb Lecture, University of Maryland
- 2008 Robert B. Greenblatt Distinguished Lecture, Medical College of Georgia
- 2008 Louis-Jeantet Foundation 25<sup>th</sup> Anniversary Symposium, Geneva, Switzerland
- 2008 Banting and Best Lecture, Canadian Diabetes Association, Montreal, Canada
- 2008 Johns Hopkins 100<sup>th</sup> Anniversary Symposium for Department of Biochemistry, Baltimore, Maryland
- 2008 Honorary Doctor in Medicine, University of Copenhagen, Denmark
- 2008 Presidential Distinguished Lecture, University of San Antonio Health Science Center, San Antonio, Texas
- 2008 Dewitt Goodman Lecture, Columbia University School of Medicine, New York, NY
- 2009 Lydia J. Roberts Lecture, University of Chicago and Chicago Nutrition Society, Chicago, IL
- 2009 Inaugural Recipient Manpei Suzuki International Prize, Tokyo, Japan
- 2009 Distinguished Visiting International Lecturer, University of Toronto
- 2009 Hans Falk Memorial Lecture, National Institute of Environmental Health Science, Research Triangle Park, NC
- 2010 Presidential Lecture, Memorial Sloan Kettering Cancer Institute, New York
- 2010 David Seegal Alpha Omega Alpha Visiting Professor, Columbia University Medical School, New York, NY

## **PART II: Research, Teaching and Clinical Contributions**

### **A. Narrative report of Research, Teaching and Clinical Contributions.**

My laboratory is focused in four highly related and integrated areas: 1) mechanisms of insulin receptor signaling in control of metabolism and growth; 2) how insulin signaling is altered in insulin resistant states such as type 2 diabetes and obesity; 3) the development of adipose tissue and its relationship to insulin resistance; and 4) what is the impact of genetics, environment and aging on these processes.

In early work, we discovered that the insulin receptor is an insulin-stimulated receptor tyrosine kinase which initiates a complex intracellular network leading to the multiple actions of insulin on the cell. Following activation of the receptor kinase, several intracellular substrates become tyrosine phosphorylated, the best studied of which are termed insulin receptor substrates-1, 2, 3 and 4 (IRS-1 thru -4). These phosphorylated IRS proteins serve as intracellular messengers by docking to other intracellular signaling proteins that contain SH2 domains. This links insulin to two major intracellular cascades - one mediated by the enzyme phosphatidylinositol 3-kinase (PI 3-kinase) and the other mediated by the Ras-MAP kinase pathway. These form a series of critical nodes in the insulin signaling network and are important points of diversion in insulin signaling. We have shown that both the receptor itself and many of its downstream signaling events are important points of regulation in normal physiology and disease states.

Using a wide range of genetic and biochemical approaches, as well as cellular, animal and human systems, my laboratory is working to define the specific pathways that lead to each of insulin's actions and how they are modified in insulin resistant states. This includes defining the roles of each of the IRS-proteins, isoforms of PI 3-kinase and their downstream kinases (Akt and atypical PKCs), in insulin signaling and insulin resistance through the creation of cell lines and animal models in which these proteins are either eliminated by a genetic "knock-out" or knocked-down using RNAi. This also includes studies utilizing the technique of tissue specific gene inactivation to determine the role of insulin in various tissues of the body, including classical target tissues for insulin action such as liver, muscle and fat, as well as non-classical targets such as the brain, endothelial cell and beta cell. We also study mechanisms of insulin resistance, including the role of regulation of insulin receptor, IRS proteins, different catalytic and regulatory subunits of PI 3- kinase, as well as other molecules that can act directly or indirectly as inhibitors of insulin action, such as some forms of protein kinase C and the sirtuin protein deacetylases.

To identify genetic alterations that might contribute to the development of type 2 diabetes in humans and rodents, we have assessed gene expression and function using microarray analysis, proteomics and other techniques. This has allowed us to answer questions about which components of the insulin signaling cascade are involved in regulation of different pathways and to dissect insulin vs. diabetes regulated events. More recently, we have added the study of microRNAs as targets and regulators of insulin action.

The biology of adipocytes and their special role in insulin resistance is another major area of interest. Here we are focused on understanding the role of various fat depots in insulin resistance, and what determines fat distribution and the nature of adipocyte lineages, including

the formation of brown vs. white fat and subcutaneous vs. intra-abdominal fat. We have found important roles for a variety of fundamental developmental genes, and are exploring these through the creation of knockout and knockdown mouse and cellular models.

Finally, we are also interested in the problem of aging and the relationship between insulin action, obesity and lifespan. Again we have taken advantage of some of our genetic models to define better the physiological connections between these events. We are now studying several pathways involved in the connection between aging and metabolism at the molecular level. In this area, we also have been studying the role of sirtuins, especially Sirt2 and Sirt3, in aging and metabolic control.

## **B. Funding Information (present and recent)**

### Present:

1980-2015	National Institutes of Health	Prin. Invest.	Insulin Receptor Structure and Turnover
1988-2013	National Institutes of Health	Prin. Invest.	Insulin Receptor Phosphorylation and Insulin Action
1992-2011	American Diabetes Association	Prog. Dir.	ADA Mentor-based Grant
1999-2012	National Institutes of Health	Prin. Invest.	Role of PI 3-kinase Isoforms in Insulin Action
2002-2009	National Institutes of Health	Prin. Invest.	Diabetes Genome Anatomy Project (DGAP)
2009-2014	National Institutes of Health	Prin. Invest.	Developmental Genes and the Origin of Fat
2009-2011	National Institutes of Health	Prin. Invest.	Imaging Strategies to Measure Brown Fat and its Activity
1996-2001	National Institutes of Health	Prog. Dir.	Diabetes and Endocrinology Research Center
1981-2001	National Institutes of Health	Prog. Dir.	Training in Diabetes and Metabolism
1998-2003	Juvenile Diabetes Foundation (JDF Center for Islet Transplantation at HMS)	Investigator	Search for Islet Growth Factors in Animal Models of Insulin Resistance

## **C. Report of Teaching Experience:**

1976-1978	Course director, "Correlations between the basic sciences and internal medicine," Foundation for Advanced Education in the Sciences, NIH.
1967-1981	Lecturer, Courses in Internal Medicine and Endocrinology, Foundation for Advanced Education in Sciences, NIH.
1977-1979	Course developer and coordinator, "Endocrinology Board Review Course," Foundation for Advanced Education in the Sciences, NIH.
1978-1981	Thesis supervisor for Ph.D. in genetics for J.M. Podskalny, George Washington University
1974	Participation in a variety of CME courses throughout the U.S.
1984	Research Supervisor, Cell and Developmental Biology Program, Harvard Medical School
1987	Thesis Committee for Ph.D. in Cell Biology, Laird D. Madison, Yale University
1981-present	Physiology, Cell Biology and Human Systems Courses at Harvard Medical

School and MIT.  
1985-present HST-060/061 Endocrinology Course, Massachusetts Institute of Technology  
1986-present HST-140/141 Molecular Medicine Course  
1989-1994 Thesis supervisor, Harvard Cell and Developmental Biology Program  
1989-1992 Appeals Board, Student Promotions Board, Faculty of Medicine, Harvard Medical School  
1994- present Graduate Faculty of BBS, Harvard Medical School  
2002-2006 Thesis supervisor for Ph.D. in Cell Biology C. Taniguchi, Harvard Medical School

**D. Report of Clinical Activities:**

1981-1990 Chief, Division of Diabetes and Metabolism, Brigham and Women's Hospital, Boston, MA  
-one month per year attending on Endocrine service  
1987- Active Staff, Beth Israel Deaconess Medical Center, Boston, MA

### **PART III: Bibliography**

#### **Original Reports:**

1. Kahn CR, Huseby RM, Murray M. The use of infrared dichronic absorption spectra in the study of the structure of bovine fibrinogen and fibrin. *Life Sci.* 1970; 9:1125-1132.
2. Freychet P, Kahn CR, Roth J, Neville DM, Jr. Insulin interactions with liver plasma membranes: Independence of binding and degradation. *J Biol Chem.* 1972; 247:3953-3961.
3. Kahn CR, Neville DM, Jr., Gorden P, Freychet P, Roth J. Insulin receptor defect in insulin resistance: Studies in the obese hyperglycemic mouse. *Biophys Biochem Res Commun.* 1972; 48:135-142.
4. Freychet P, Laudat MH, Laudat P, Rosselin G, Kahn CR, Gorden P, Roth J. Impairment of insulin binding to the fat cell membrane in the obese hyperglycemic mouse. *FEBS Lett.* 1972; 25:339-342.
5. Kahn CR, Neville DM, Jr., Roth J. Insulin-receptor interactions in the obese-hyperglycemic mouse: A model for insulin resistance. *J Biol Chem.* 1973; 248:244-250.
6. Freychet P, Kahn CR, Roth J, Neville DM, Jr. Insulin receptor in liver cell plasma membranes. In: Scow R, ed. *Endocrinology: Proceedings of the IV International Congress of Endocrinology.* New York: Excerpta Medica (ICS #273). NY, 1973:335-340.
7. Schein P, Kahn CR, Gorden P, Wells S, DeVita V. Streptozotocin therapy of malignant insulinoma and carcinoid tumor. *Arch Intern Med.* 1973; 132:555-561.
8. Pilch B, Kahn CR, Ketcham A, Henson D. Thyroid cancer after radioactive iodine diagnostic procedures in childhood. *Pediatrics.* 1973; 51:898-902.
9. Schein PS, DeLellis RA, Kahn CR, Gorden P, Kraft AR. Islet cell tumors: Current concepts and management. *Ann Intern Med.* 1973; 79:239-257.
10. Goldfine ID, Kahn CR, Neville DM, Jr., Roth J, Garrison MM, Bates RW. Decreased binding of insulin to its receptors in rats with hormone induced insulin resistance. *Biochem Biophys Res Commun.* 1973; 53:852-857.
11. Butcher RW, Crofford OB, Gammeltoft S, Gliemann J, Gavin JR III, Goldfine ID, Kahn CR, Rodbell M, Roth J. Insulin activity: The solid matrix. *Science.* 1973; 182:396-397.
12. Kahn CR, Freychet P, Neville DM, Jr., Roth J. Quantitative aspects of the insulin-receptor interaction in liver plasma membranes. *J Biol Chem.* 1974; 249:2249-2257.
13. Gorden P, Roth J, Hendricks CM, Kahn CR. The plasma proinsulin-like components. *Isr J Med Sci.* 1974; 10:1212-1221.
14. Megyesi K, Kahn CR, Roth J, Froesch ER, Humbel RE, Zapf J, Neville DM, Jr. Insulin

- and non-suppressible insulin-like activity (NSILA-s): Evidence for separate plasma membrane receptor sites. *Biochem Biophys Res Commun.* 1974; 57:307-315.
15. Megyesi I, Kahn CR, Roth J, Gorden P. Hypoglycemia in association with extrapancreatic tumors: Demonstration of elevated plasma NSILA-s by a new radio-receptor assay. *J Clin Endocrinol Metab.* 1974; 38:931-934.
  16. McGuffin WL, Jr., Sherman BM, Roth J, Gorden P, Kahn CR, Roberts WC, Frommer PL. Acromegaly and cardiovascular disorders: A prospective study. *Ann Intern Med.* 1974; 81:11-18.
  17. Soll AH, Goldfine ID, Roth J, Kahn CR, Neville DM, Jr. Thymic lymphocytes in obese (ob/ob) mice: Mirror of the insulin receptor defect in liver and fat. *J Biol Chem.* 1974; 249:4127-4131.
  18. Thomas DW, Rosen SW, Kahn CR, Temple R, Papadopoulous NM. Macromolecular lactic acid dehydrogenase: A cause of increased serum lactate dehydrogenase activity. *Ann Intern Med.* 1974; 81:434-439.
  19. Soll AH, Kahn CR, Neville DM, Jr. Insulin binding to liver plasma membranes in the obese hyperglycemic (ob/ob) mouse: Demonstration of a decreased number of functionally normal receptors. *J Biol Chem.* 1975; 250:7402-7407.
  20. Kahn CR, Levy AG, Gardner JD, Miller JV, Gorden P, Schein P. Pancreatic cholera: Beneficial effects of treatment with streptozotocin. *N Engl J Med.* 1975; 292:941-945.
  21. Megyesi K, Kahn CR, Roth J, Gorden P. Circulating NSILA-s in man: Preliminary studies of stimuli in vivo and of binding to plasma components. *J Clin Endocrinol Metab.* 1975; 41:475-484.
  22. Schwartz RH, Bianco AR, Handwerger BS, Kahn CR. Demonstration that monocytes rather than lymphocytes are the insulin-binding cells in preparations of human peripheral mononuclear leukocytes: Implications for studies of insulin resistant states in man. *Proc Natl Acad Sci. USA* 1975; 72:474-478.
  23. Gavin JR, III, Kahn CR, Gorden P, Roth J, Neville DM, Jr., Radioreceptor assay of insulin: Comparison of plasma and pancreatic insulins and proinsulins. *J Clin Endocrinol Metab.* 1975; 41:438-445.
  24. Soll AH, Kahn CR, Neville DM, Jr., Roth J. Insulin receptor deficiency in genetic and acquired obesity. *J Clin Invest.* 1975; 56:769-780.
  25. Megyesi K, Kahn CR, Roth J, Neville DM, Jr., Nissley SP, Humbel RE, Froesch ER. The NSILA-s receptor in liver plasma membranes: Characterization and comparison with the insulin receptor. *J Biol Chem.* 1975; 250:8990-8996
  26. Flier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. *Science.* 1975; 190:63-65.

27. Kibata M, Hiramatsu K, Shimizu Y, Fuchimoto T, Sasaki N, Shimono M, Miyake K, Flier JS, Kahn CR. Insulin receptor antibody found in a case of Sjogren's syndrome associated with extreme insulin-resistant diabetes. Proceedings of the Symposium on Chemical Physiology and Pathology. (Japan) 1975; 15:58-63.
28. Kahn CR, Megyesi K, Roth J. Nonsuppressible insulin-like activity of human serum: A potent inhibitor of insulin degradation. J Clin Invest. 1976; 57:526-529.
29. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans: Insulin receptor disorders in man. N Engl J Med. 1976; 294:739-745.
30. Ginsberg BH, Kahn CR, Roth J. The insulin receptor of the turkey erythrocyte: Purification and characterization of the membrane bound receptor. Biochem Biophys Acta. 1976; 443:227-242.
31. Fussganger RD, Kahn CR, Roth J, De Meyts P. Binding and degradation of insulin by human peripheral granulocytes: Demonstration of specific receptors with high affinity. J Biol Chem. 1976; 251:2761-2769.
32. Rogol AD, Kahn CR. Congenital hypothyroidism in a young man with growth hormone, thyrotropin and prolactin deficiencies. J Pediatr. 1976; 88:953-958.
33. Bar RS, Gorden P, Roth J, Kahn CR, De Meyts P. Fluctuation in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: Effects of starvation, refeeding and dieting. J Clin Invest. 1976; 58:123-1135.
34. Flier JS, Kahn CR, Jarrett DB, Roth J. Characterization of anti-insulin receptor antibodies: A cause of insulin resistant diabetes in man. J Clin Invest. 1976; 58:1442-1449.
35. Flier JS, Kahn CR, Jarrett DB, Roth J. The immunology of the insulin receptor. Immunol Commun. 1976; 5:361-373.
36. Jarrett DB, Roth J, Kahn CR, Flier JS. A new direct method for detection and characterization of cell surface receptors for insulin using <sup>125</sup>I-anti-receptor autoantibodies. Proc Natl Acad Sci. USA 1976; 73:4115-4119.
37. Ginsberg BH, Kahn CR, Roth J, De Meyts P. Insulin-induced dissociation of its receptor into subunits: Possible molecular concomitant of negative cooperativity. Biochem Biophys Res Commun. 1976; 73:1068-1074.
38. Kawanishi K, Kawamura K, Nishina AG, Okada S, Ishida T, Ofuji T, Kahn CR, Flier JS. Successful immunosuppressive therapy in insulin resistant diabetes caused by anti-insulin receptor autoantibodies. J Clin Endocrinol Metab. 1977; 44:15-21.
39. Ginsberg B, Kahn CR, Roth J. The insulin receptor of the turkey erythrocyte: Similarity to mammalian insulin receptors. Endocrinology. 1977; 100:82-90.

40. Kahn CR, Megyesi K, Bar RS, Eastman RC, Flier JS. Receptors for peptide hormones: New insights into the pathophysiology of disease states in man. *Ann Intern Med.* 1977; 86:205-219.
41. Eastman RC, Come SE, Strewler GJ, Gorden P, Kahn CR. Adriamycin therapy for advanced insulinoma. *J Clin Endocrinol Metab.* 1977; 44:142-148.
42. Bar BS, Koren HS, Kahn CR. Insulin inhibition of antibody-dependent cytotoxicity and insulin receptors in macrophages. *Nature.* 1977; 265:632-635.
43. Hyodo T, Megyesi K, Kahn CR, McLean JP, Friesen HG. Adrenocortical carcinoma and hypoglycemia: Evidence for production of non-suppressible insulin-like activity by the tumor. *J Clin Endocrinol Metab.* 1977; 44:1175-1184.
44. Megyesi K, Gorden P, Kahn CR. Lack of a simple relationship between endogenous growth hormone and NSILA-s related peptides. *J Clin Endocrinol Metab.* 1977; 45:330-338.
45. Flier JS, Kahn CR, Jarrett DB, Roth J. Autoantibodies to the insulin receptor: Effect of the insulin-receptor interaction in IM-9 lymphocytes. *J Clin Invest.* 1977; 60:784-794.
46. Kahn CR, Rosen SW, Weintraub BD, Fajans SS, Gorden P. Ectopic production of chorionic gonadotropin and its subunits by islet cell tumors: A specific marker for malignancy. *N Engl J Med.* 1977; 297:565-569.
47. Kahn CR, Baird KL, Flier JS, Jarrett DB. Effect of autoantibodies to the insulin receptor on isolated adipocytes: Studies of insulin binding and insulin action. *J Clin Invest.* 1977; 60:1094-1106.
48. Goldfine ID, Vigneri R, Cohen D, Pilam NB, Kahn CR. Evidence that intracellular binding sites for insulin are immunologically distinct from those on the plasma membrane. *Nature.* 1977; 269:698-700.
49. Osborne CK, Monoco ME, Lippman ME, Kahn CR. Correlation between insulin binding, degradation and biological activity in human breast cancer cell lines in long-term tissue culture. *Cancer Res.* 1978; 38:94-102.
50. Carpentier JL, Gorden P, Amherdt M, Van Obberghen E, Kahn CR, Orci L. <sup>125</sup>I-insulin binding to cultured lymphocytes: Initial localization and fate of hormone determined by quantitative electron microscopic autoradiography. *J Clin Invest.* 1978; 61:1057-1070.
51. LeMarchand-Brustel Y, Gorden P, Flier JS, Kahn CR, Freychet P. Anti-insulin receptor antibodies inhibit insulin binding and stimulate glucose metabolism in skeletal muscle. *Diabetologia.* 1978; 14:311-318.
52. Bar RS, Muggeo M, Roth J, Kahn CR, Havrankova J, Imperato-McGinley J. Insulin resistance, acanthosis nigricans and normal insulin receptors in a young woman: Evidence for a post-receptor defect. *J Clin Endocrinol Metab.* 1978; 47:620-625.

53. Kahn CR, Baird KL. The fat of insulin bound to adipocytes: Evidence for compartmentalization and processing. *J Biol Chem.* 1978; 273:4900-4906.
54. Ginsberg BH, Cohen RM, Kahn CR, Roth J. Properties and partial purification of the detergent solubilized insulin receptor: A demonstration of negative cooperativity in micellar solution. *Biochem Biophys Acta.* 1978; 542:88-100.
55. Kahn CR. Insulin resistance, insulin insensitivity and insulin unresponsiveness: A necessary distinction. *Metabolism.* 1978; 27:1893-1902.
56. Doppman JL, Girtan M, Kahn CR. Proximal vs. peripheral hepatic arterial embolization: Experimental study in monkeys. *Radiology.* 1978; 128:577-578.
57. Kahn CR, Goldfine ID, Neville DM, Jr., De Meyts P. Alterations in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. *Endocrinology.* 1978; 103:1054-1066.
58. Flier JS, Bar RS, Muggeo M, Kahn CR, Roth J, Gorden P. The evolving clinical course of patients with insulin receptor antibodies: Spontaneous remission or receptor proliferation with hypoglycemia. *J Clin Endocrinol Metab.* 1978; 47:985-995.
59. Kahn CR, Baird KL, Jarrett DB, Flier JS. Direct demonstration that receptor cross-linking or aggregation is important in insulin action. *Proc Natl Acad Sci. USA* 1978; 75:4209-4213.
60. Lawrence JC, Jr., Larner J, Kahn CR, Roth J. Antibodies to the insulin receptor stimulate glycogen synthase in rat adipocytes. *Mol Cell Biochem.* 1978; 22:153-158.
61. Flier JS, Kahn CR, Roth J. Receptors, anti-receptor antibodies and the mechanism of insulin resistance. *N Engl J Med.* 1979; 33:413-419.
62. Ginsberg BH, Kahn CR, Roth J, Megyesi K, Baumann G. Identification and high-yielded purification of insulin-like growth factors (NSILA-s and somatomedins) from human plasma by use of endogenous binding proteins. *J Clin Endocrinol Metab.* 1979; 48:43-49.
63. Harrison LC, Flier JS, Roth J, Karlsson FA, Kahn CR. Immunoprecipitation of the insulin receptor: A sensitive assay for receptor antibodies and a specific technique for receptor purification. *J Clin Endocrinol Metab.* 1979; 48:59-65.
64. Muggeo M, Bar RS, Roth J, Kahn CR. The insulin resistance acromegaly: Evidence for two alterations in the insulin receptor on circulating monocytes. *J Clin Endocrinol Metab.* 1979; 48:17-25.
65. Muggeo M, Van Obberghen E, Kahn CR, Roth J, Ginsberg BH, De Meyts P, Emdin SO, Falkmer S. The insulin receptor and insulin of the Atlantic hagfish: Extraordinary conservation of binding specificity and negative cooperativity in the most primitive vertebrate. *Diabetes.* 1979; 28:175-187.
66. Harrison LC, Flier JS, Itin A, Kahn CR, Roth J. Radioimmunoassay of the insulin

- receptor: A new probe of receptor structure and function. *Science*. 1979; 203:544-547.
67. Karlsson FA, Van Obberghen E, Grunfeld C, Kahn CR. Desensitization of the insulin receptor at an early post-receptor step by prolonged exposure to anti-receptor antibody. *Proc Natl Acad Sci. USA* 1979; 76:809-813.
  68. Muggeo M, Flier JS, Abrams RA, Harrison LC, Deisseroth AB, Kahn CR. Treatment by plasma exchange of a patient with autoantibodies to the insulin receptor. *N Engl J Med*. 1979; 300:477-480.
  69. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: Insulin allergy, insulin resistance and the autoimmune insulin syndrome. *Diabetes Care*. 1979; 2:283-295.
  70. Norton JA, Kahn CR, Schiebinger R, Gorschborth C, Brennan MF. The role of amino acid deficiency in the skin rash associated with glucagonoma. *Ann Intern Med*. 1979; 91:213-215.
  71. Karlsson FA, Grunfeld C, Kahn CR, Roth J. Regulation of insulin receptors and insulin responsiveness in 3T3-L1 fatty fibroblasts. *Endocrinology*. 1979; 104:1383-1392.
  72. Muggeo M, Ginsberg BH, Roth J, Neville DM, Jr., De Meyts P, Kahn CR. The insulin receptor in vertebrates is functionally more conserved during evolution than insulin itself. *Endocrinology*. 1979; 104:1393-1402.
  73. Mills SR, Doppman JL, Kahn CR. Metastatic islet cell carcinoma to the liver visualized after intra-arterial epinephrine. *Am J Radiol*. 1979; 132:664-665.
  74. Van Obberghen E, Spooner PM, Kahn CR, Chernick SS, Garrison MM, Karlsson FA, Grunfeld C. Antibodies against the insulin receptor mimic a long-term insulin effect. *Nature*. 1979; 280:500-502.
  75. Muggeo M, Kahn CR, Bar RS, Rechler MM, Flier JS, Roth J. The underlying receptor in patients with anti-receptor autoantibodies: Demonstration of normal binding and immunologic properties. *J Clin Endocrinol Metab*. 1979; 49:100-119.
  76. Kahn CR. What is the molecular basis for insulin action? *Trends in Biochemical Sciences*. 1979; 263:4-7.
  77. Osborne CK, Monaco ME, Kahn CR, Huff K, Bronzert D, Lippman ME. Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. *Cancer Res*. 1979; 39:2422-2428.
  78. Lang U, Kahn CR, Chrambach A. Characterization of the insulin receptor and insulin-degrading activity from human lymphocytes by quantitative polyacrylamide gel electrophoresis. *Endocrinology*. 1980; 106:40-49.
  79. Bar RS, Muggeo M, Kahn CR, Gorden P, Roth J. Characterization of the insulin receptors in patients with the syndromes of insulin resistance and acanthosis nigricans. *Diabetologia*. 1980; 18:209-216.

80. Lang U, Kahn CR, Harrison LC. The subunit structure of the insulin receptor of the human lymphocyte. *Biochemistry*. 1980; 19:64-70.
81. Harmon JT, Kahn CR, Kempner ES, Schlegel W. Characterization of the insulin receptor in its membrane environment by radiation inactivation. *J Biol Chem*. 1980; 255:3412-3419.
82. Kahn CR. The riddle of tumor hypoglycemia revisited. *J Clin Endocrinol Metab*. 1980; 9:335-360.
83. King GL, Kahn CR, Rechler MM, Nissley SP. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor. *J Clin Invest*. 1980; 66:130-140.
84. Kahn CR, Podskalny JM. Demonstration of a primary (? genetic) defect in insulin receptors in fibroblasts from a patient with the syndrome of insulin resistance and acanthosis nigricans Type A. *J Clin Endocrinol Metab*. 1980; 50:1139-1141.
85. Schlessinger J, Van Obberghen E, Kahn CR. Insulin and antibodies against the insulin receptor-cap on the membrane of cultured human lymphocytes. *Nature*. 1980; 286:729-731.
86. Podskalny JM, Kahn CR. Insulin activates glycogen synthase in cultured human fibroblasts. *Diabetes*. 1980; 29:724-729.
87. Grunfeld C, Van Obberghen E, Karlsson FA, Kahn CR. Antibody-induced desensitization of the insulin receptor: Studies of the mechanism of desensitization in 3T3-L1 fatty fibroblasts. *J Clin Invest*. 1980; 66:1124-1134.
88. Shimizu F, Hooks JJ, Kahn CR, Notkins AL. Virus-induced decrease of insulin receptors. *J Clin Invest*. 1980; 66:1144-1151.
89. Doppman JL, Brennan MF, Dunnick NR, Kahn CR, Gorden P. The role of pancreatic venous sampling in localization of occult insulinomas. *Radiology*. 1981; 137:557-562.
90. Harmon JT, Kahn CR, Kempner ES, Johnson ML. Examination of the insulin receptor in membranes by radiation inactivation studies. In: Andreani D, De Pirro R, Lauro R, Olefsky JM, Roth J, eds. *Current Views on Insulin Receptors*. London: Academic Press. 1981:37-44.
91. King GL, Kahn CR. Comparative studies of insulin's metabolic and growth activities. In: Andreani D, De Pirro R, Lauro R, Olefsky J, Roth J, eds. *Current Views on Insulin Receptors*. London: Academic Press. 1981:339-346.
92. Wachslicht-Rodbard H, Muggeo M, Kahn CR, Saviolakis GA, Harrison LC, Flier JS. Heterogeneity of the insulin receptor interaction in lipoatrophic diabetes. *J Clin Endocrinol Metab*. 1981; 52:416-425.

93. Kahn CR, Bertolotti R, Ninio M, Weiss MC. Short-lived cytoplasmic regulators of gene expression in cell cybrids. *Nature*. 1981; 290:717-720.
94. Doppman JL, Brennan MF, Kahn CR, Marx SJ. Circumscribing or per adenoma vessel: A helpful angiographic finding in certain islet cell and parathyroid adenomas. *Am J Radiol*. 1981; 136:163-165.
95. Kahn CR, Bhathena SJ, Recant L, Rivier J. Use of somatostatin and somatostatin analogs in a patient with a glucagonoma. *J Clin Endocrinol Metab*. 1981; 53:543-549.
96. Hedo J, Kasuga M, Van Obberghen E, Roth J, Kahn CR. Direct demonstration of the glycosylation of insulin receptor subunits by biosynthetic and external labeling: Evidence for heterogeneity. *Proc Nat Acad Sci USA* 1981; 78:4791-4795.
97. Kahn CR, Gopalakrishnan TV, Weiss MC. Transfer of heritable properties by cell hybridization: Specificity and the role of selective pressure. *Som Cell Gen*. 1981; 7:547-565.
98. Gorden P, Hendricks CM, Kahn CR, Megyesi K, Roth J. Hypoglycemia associated with non-islet cell tumors and insulin like growth factors. *N Engl J Med*. 1981; 305:1452-1455.
99. Harmon JT, Kempner ES, Kahn CR. Demonstration by radiation inactivation that insulin alters the structure of the insulin receptor in rat liver membranes. *J Biol Chem*. 1981; 256:7719-7722.
100. Kahn CR, Baird KL, Van Obberghen E. Role of valence and the cytoskeleton in the insulin-like activity of concanavalin A. *FEBS Lett*. 1981; 129:131-134.
101. Grunfeld C, Baird KL, Van Obberghen E, Kahn CR. Glucocorticoid-induced insulin resistance in vitro: Evidence for both receptor and post-receptor defects. *Endocrinology*. 1981; 109:1723-1730.
102. Kasuga M, Kahn CR, Hedo JA, Van Obberghen E, Yamada KM. Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor degradation. *Proc Natl Acad Sci USA* 1981; 78:6917-6921.
103. Grunfeld C, Baird KL, Kahn CR. Maintenance of 3T3-L1 cells in culture media containing saturated fatty acids decreases insulin binding and insulin action. *Biochem Biophys Res Commun*. 1981; 103:219-226.
104. Podskalny JM, Kahn CR. Cell culture studies on patients with extreme insulin resistance. I. Receptor defects in cultured fibroblasts. *J Clin Endocrinol Metab*. 1982; 54:261-268.
105. Podskalny JM, Kahn CR. Cell culture studies on patients with extreme insulin resistance. II. Abnormal biological responses in cultured fibroblasts. *J Clin Endocrinol Metab*. 1982; 54:269-275.

106. Shimizu F, Kahn CR. Insulin radioreceptor assay on murine splenic leukocytes and peripheral erythrocytes. *Endocrinology*. 1982; 110:474-480.
107. Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-Dalton subunit of its own receptor. *Science*. 1982; 215:185-187.
108. King GL, Kahn CR, Samuels B, Danho W, Bullesbach EE, Crattner HG. Synthesis and characterization of molecular hybrids of insulin and insulin-like growth factors. I. Role of the A-chain extension peptide. *J Biol Chem*. 1982; 257:10869-10873.
109. Kasuga M, Zick Y, Bliethe DL, Karlsson FA, Haring H-U, Kahn CR. Insulin stimulation of phosphorylation of the  $\beta$ -subunit of the insulin receptor: Formation of both phosphoserine and phosphotyrosine. *J Biol Chem*. 1982; 257:9891-9894.
110. Goren HJ, Kahn CR. Effect of cross-linking agents on insulin associated responses in adipocytes. *Can J Biochem*. 1982; 60:987-1000.
111. Kahn CR, Mann D, Rosenthal AS, Galloway JA, Johnson AH, Mendell N. The immune response to insulin in man: Interaction of HLA alloantigens and the development of the immune response. *Diabetes*. 1982; 31:716-723.
112. Kasuga M, Hedo JA, Yamada KM, Kahn CR. The structure of the insulin receptor and its subunits: Evidence for multiple non-reduced forms and a 210K possible proreceptor. *J Biol Chem*. 1982; 257:10392-10399.
113. Karlsson FA, Harrison LC, Kahn CR, Itin A, Roth J. Subpopulations of antibodies directed against evolutionarily conserved regions of the insulin molecule in insulin treated patients. *Diabetologia*. 1982; 23:488-493.
114. Wang C-C, Hedo JA, Kahn CR, Saunders DT, Thamm P, Brandenburg D. Photoreactive insulin derivatives: Comparison of biological activity and labeling properties of three analogues in isolated rat adipocytes. *Diabetes*. 1982; 31:1068-1076.
115. King GL, Rechler MM, Kahn CR. Interactions between the receptors for insulin and the insulin-like growth factors on adipocytes. *J Biol Chem*. 1982; 257:10001-10006.
116. Kasuga M, Zick Y, Bliethe DL, Crettaz M, Kahn CR. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a "cell-free" system. *Nature*. 1982; 298:667-669.
117. Haring HU, Kasuga M, Kahn CR. Insulin receptor phosphorylation in intact adipocytes and in a cell-free system. *Biochem Biophys Res Commun*. 1982; 108:1538-1545.
118. Podskalny JM, Kahn CR. Insulin binding and activation of glycogen synthase in fibroblasts from Type I (insulin-dependent) diabetic patients. *Diabetologia*. 1982; 23:431-435.
119. Knorr R, Danho W, Bullesbach EE, Gattner H-G, Zahn H, King GL, Kahn CR. B-22-D-

- arginine insulin: Synthesis and biological properties. *Hoppe-Seyler's Z. Physiol Chem.* 1982; 363:1449-1460.
120. Kahn CR, Gang DL. A 37-year-old schizophrenic woman with hypoglycemia episodes (case records of the Massachusetts General Hospital). *N Engl J Med.* 1983; 308:30-36.
  121. Zick Y, Kasuga M, Kahn CR, Roth J. Characterization of insulin-mediated phosphorylation of the insulin receptor in a cell-free system. *J Biol Chem.* 1983; 258:75-80.
  122. King GL, Kahn CR, Heldin C-H. Sharing of biological effect and receptors between guinea pig insulin and platelet-derived growth factor. *Proc Natl Acad Sci. USA* 1983; 80:1308-1312.
  123. Harmon JT, Hedo JA, Kahn CR. Characterization of a membrane regulator of insulin receptor affinity. *J Biol Chem.* 1983; 258:6875-6881.
  124. Crettaz M, Kahn CR, Fehlmann M. Glucagon regulation of amino acid transport in hepatocytes: Effect of cell enucleation. *J Cell Physiol.* 1983; 115:186-190.
  125. Kasuga M, Fujita-Yamaguchi Y, Blithe DL, Kahn CR. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. *Proc Natl Acad Sci. USA* 1983; 80:2137-2141.
  126. Kahn CR, Lauris V, Fehlmann M, Crettaz M. Expression of insulin receptors and insulin action in cell hybrids and cybrids. *Biochem J.* 1983; 214:309-316.
  127. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, MacDonald SG, Rand LI. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. *J Clin Invest.* 1983; 71:974-979.
  128. Blackshear PJ, Rotner HE, Kriauciunas KM, Kahn CR. Reactive hypoglycemia and insulin autoantibodies in a patient with drug-induced lupus erythematosus. *Ann Intern Med.* 1983; 99:182-184.
  129. Maratos-Flier E, Kahn CR, Fields BN, Spriggs DR. Specific plasma membrane receptors for reovirus in pituitary cells in culture. *J Clin Invest.* 1983; 72:617-621.
  130. Crettaz M, Kahn CR. Analysis of insulin action using differentiated and dedifferentiated hepatoma cells. *Endocrinology.* 1983; 113:1201-1209.
  131. Fehlmann M, Crettaz M, Kahn CR. Glucagon resistance of hepatoma cells: Evidence for receptor and post-receptor defects. *Biochem J.* 1983; 214:845-850.
  132. Grigorescu F, White MF, Kahn CR. Insulin binding and insulin-dependent phosphorylation of the insulin receptor solubilized from human erythrocytes. *J Biol Chem.* 1983; 258:13708-13716.
  133. Hedo JA, Kahn CR, Hayashi M, Yamada KM, Kasuga M. Biosynthesis and glycosylation

- of the insulin receptor: Evidence for a single polypeptide precursor of the two major subunits. *J Biol Chem.* 1983; 258:10020-10026.
134. Kasuga M, Fujita-Yamaguchi Y, Blithe DL, White MF, Kahn CR. Characterization of the insulin receptor kinase purified from human placental membranes. *J Biol Chem.* 1983; 258:10973-10980.
  135. Mann DL, Mendell N, Kahn CR, Johnson AH, Rosenthal A. In vitro lymphocyte proliferation response to therapeutic insulin components: Evidence for genetic control by the human major histocompatibility complex. *J Clin Invest.* 1983; 72:1130-1138.
  136. Kahn CR. The insulin receptor and insulin: The lock and key to diabetes. *Clin Res.* 1983; 31:326-335.
  137. Kasuga M, Sasaki N, Kahn CR, Nissley SP, Rechler MM. Anti-receptor antibodies as probes of insulin-like growth factor receptor structure. *J Clin Invest.* 1983; 72:1459-1469.
  138. Shimizu F, Kahn CR, Barzelli C, Hooks JJ, Notkins AL. The binding of insulin to mouse leukocyte during viral infections. *Diabetologia.* 1983; 25:521-524.
  139. White MF, Haring HU, Kasuga M, Kahn CR. Kinetic properties and sites of autophosphorylation of the partially purified insulin receptor from hepatoma cells. *J Biol Chem.* 1984; 259:255-264.
  140. Kahn CR. A proposed new role of the insurance industry in biomedical research funding. *N Engl J Med.* 1984; 310:257-258.
  141. Haring HU, Kasuga M, White MF, Crettaz M, Kahn CR. Phosphorylation and dephosphorylation of the insulin receptor: Evidence against an intrinsic phosphatase activity. *Biochemistry.* 1984; 23:3298-3306.
  142. Crettaz M, Kahn CR. Insulin receptor regulation and desensitization in rat hepatoma cells. Concomitant changes in receptor number and binding affinity. *Diabetes.* 1984; 33:477-485.
  143. Sodoyez JC, Sodoyez-Goffaux F, Treves S, Kahn CR, von Frenckell R. In vivo imaging and quantitative analysis of insulin receptor interaction in lean and obese Zucker rats. *Diabetologia.* 1984; 26:229-233.
  144. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. *N Engl J Med.* 1984; 23:149-152.
  145. Maron R, Taylor SI, Jackson R, Kahn CR. Analysis of insulin receptor on human lymphoblastoid cell lines by flow cytometry. *Diabetologia.* 1984; 27:118-120.
  146. Gruppuso PA, Gorden P, Kahn CR, Cornblath M, Zeller WP, Schwartz R. Familial hyperproinsulinemia due to a proposed defect in proinsulin to insulin conversion. *N Engl J Med.* 1984; 311:629-634.

147. Jialal I, King GL, Buchwald S, Kahn CR, Crettaz M. Processing of insulin by bovine endothelial cells in culture: Internalization without degradation. *Diabetes*. 1984; 33:794-800.
148. Haring HU, White MF, Kahn CR, Kasuga M, Lauris V, Fleischmann R, Murray M, Pawelek J. Abnormality of insulin binding and receptor phosphorylation in an insulin-resistant melanoma cell line. *J Cell Biol*. 1984; 99:900-908.
149. Crettaz M, Jialal I, Kasuga M, Kahn CR. Insulin receptor regulation and desensitization in rat hepatoma cells: The loss of the oligomeric forms of the receptor correlates with the change in receptor affinity. *J Biol Chem*. 1984; 259:11543-11549.
150. Maron R, Kahn CR, Jacobs S, Fujita-Yamaguchi Y. Visualization of the insulin receptor by immunoblotting. *Diabetes*. 1984; 33:923-928.
151. Grigorescu F, Flier JS, Kahn CR. Defect in insulin receptor phosphorylation in erythrocytes and fibroblasts associated with severe insulin resistance. *J Biol Chem*. 1984; 259:15003-15006.
152. Maron R, Jackson RA, Jacobs S, Eisenbarth G, Kahn CR. Analysis of the insulin receptor by anti-receptor antibodies and flow cytometry. *Proc Natl Acad Sci. USA* 1984; 81:7446-7450.
153. Takayama S, White MF, Lauris V, Kahn CR. Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells. *Proc Natl Acad Sci. USA* 1984; 81:7797-7801.
154. White MF, Werth DK, Pastan I, Kahn CR. Phosphorylation of the solubilized insulin receptor by the gene product of the rous sarcoma virus, pp60<sup>src</sup>. *J Cell Biochem*. 1984; 26:169-179.
155. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. *J Clin Invest*. 1985; 75:1028-1036.
156. Kahn CR. The molecular mechanism of insulin action: Current concepts of the molecular mechanism of insulin action. In: Creger WP, ed. *Annual Review of Medicine*. Palo Alto: Annual Reviews Inc. 1985:429-451.
157. Kahn CR, Baird KL. Pathways of insulin degradation in isolated adipocytes: Evaluation by gel filtration and differential precipitation. *Metabolism*. 1985; 34:354-363.
158. Maron R, Kahn CR. The insulin receptor: Characterization and regulation using insulin-anti-insulin antibody complexes as a probe for flow cytometry. *J Clin Endocrinol Metab*. 1985; 60:1004-1011.
159. Maratos-Flier E, Goodman M, Fields BN, Kahn CR. Differential effects of viral infection on islet and pituitary cells in culture. *Endocrinology*. 1985; 116:2430-2437.

160. Sodoyez JC, Sodoyez-Goffaux FR, Treves S, Kahn CR. Kinetics and biodistribution of <sup>123</sup>I-insulin in the rat by in vivo imaging: Effects of an antiserum to the insulin receptor. *J Clin Invest.* 1985; 75:1455-1562.
161. Pang DT, Baldev SR, Sharma R, Shafer JA, White MF, Kahn CR. Predominance of tyrosine phosphorylation of insulin receptor during the initial response of intact cells to insulin. *J Biol Chem.* 1985; 260:7131-7136.
162. Haring HU, White MF, Kahn CR, Ahmed Z, DePaoli-Roach AA, Roach PJ. Interaction of the insulin receptor kinase with serine/threonine kinases in vivo. *J Cell Biochem.* 1985; 28:171-182.
163. Herzberg VL, Grigorescu F, Edge SB, Spiro RG, Kahn CR. Characterization of insulin receptor carbohydrate by comparison of chemical and enzymatic deglycosylation. *Biochem Biophys Res Commun.* 1985; 129:789-796.
164. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy of Type I diabetes. *Am J Med.* 1985; 78:785-794.
165. White MF, Takayama S, Kahn CR. Differences in the sites of phosphorylation of the insulin receptor in vivo and in vitro. *J Biol Chem.* 1985; 260:9470-9478.
166. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, King GL. Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. *Endocrinology.* 1985; 117:1222-1229.
167. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of an M<sub>r</sub> 185,000 protein in intact cells. *Nature.* 1985; 318:183-186.
168. Beguinot F, Kahn CR, Moses AC, Smith RJ. Distinct biologically active receptors for insulin, insulin-like growth factor-I, and insulin-like growth factor-II in cultured skeletal muscle cells. *J Biol Chem.* 1985; 260:15892-15898.
169. Crettaz M, Takayama S, Kahn CR. Structure, phosphorylation and desensitization of the insulin receptor in hepatoma cells. *Drug Res.* 1985; 35:1941-1942.
170. Beguinot F, Kahn CR, Moses AC, Smith RJ. The development of insulin receptors and responsiveness is an early marker of differentiation in the muscle cell line L6. *Endocrinology.* 1986; 118:446-455.
171. Grigorescu F, Flier JS, Kahn CR. Characterization of binding and phosphorylation defects of insulin receptors in the Type A syndrome of insulin resistance. *Diabetes.* 1986; 35:127-138.
172. Catanese VM, Grigorescu F, King GL, Kahn CR. The human erythrocyte insulin-like growth factor I receptor: Characterization and demonstration of ligand-stimulated autophosphorylation. *J Clin Endocrinol Metab.* 1986; 62:692-699.

173. Sale GJ, Fujita-Yamaguchi Y, Kahn CR. Characterization of phosphatidylinositol kinase activity associated with the insulin receptor. *Eur J Biochem.* 1986; 155:345-351.
174. Lauris V, Crettaz M, Kahn CR. Coordinate roles of insulin and glucose on the growth of hepatoma cells in culture. *Endocrinology.* 1986; 118:2519-2524.
175. Verdin EM, Maratos-Flier E, Carpentier J-L, Kahn CR. Persistent infection leads to impaired growth factor receptors and response. *J Cell Physiol.* 1986; 128:457-465.
176. Kaye WA, Adri MS, Soeldner JS, Rabinowe SL, Kaldany A, Kahn CR, Bistran B, Srikanta S, Ganda OP, Eisenbarth GS. Acquired defect in interleukin 2 production in patients with Type I diabetes mellitus. *N Engl J Med.* 1986; 315:920-925.
177. Maratos-Flier E, Goodman MJ, Murray AH, Kahn CR. Ammonium inhibits processing and cytotoxicity of reovirus. A nonenveloped virus. *J Clin Invest.* 1986; 78:1003-1007.
178. Podskalny JM, Kahn CR. Insulin activation of glycogen synthase in cultured human fibroblasts is not mediated solely via the insulin receptor. *Horm Metabol Res.* 1986; 5:335-350.
179. Krolewski AS, Warram JH, Rand LI, Christlieb AR, Busick EJ, Kahn CR. Risk of proliferative diabetic retinopathy in juvenile-onset Type I diabetes: A 40-year follow up study. *Diabetes Care.* 1986; 9:443-452.
180. Okamoto M, White MF, Maron R, Kahn CR. Autophosphorylation and kinase activity of insulin receptor in streptozotocin-induced and BB diabetic rats. *Am J Physiol.* 1986; 251:E542-E550.
181. Sale EM, White MF, Kahn CR. Phosphorylation of glycolytic and gluconeogenic enzymes by the insulin receptor kinase. *J Cell Biochem.* 1987; 33:15-26.
182. Kriauciunas KM, Grigorescu F, Kahn CR. Effects of heparin on insulin binding and biological activity. *Diabetes.* 1987; 36:163-168.
183. Grigorescu F, Herzberg V, King GL, Meistas M, Elders J, Frazer T, Kahn CR. Defects in insulin binding and autophosphorylation of erythrocyte insulin receptors in patients with syndrome of severe insulin resistance and their patients. *J Clin Endocrinol Metab.* 1987; 64:549-556.
184. Hachiya HL, Treves ST, Kahn CR, Sodoyez JC, Sodoyez-Goffaux F. Altered insulin distribution and metabolism in Type I diabetics assessed by <sup>123</sup>I-insulin scanning. *J Clin Endocrinol Metab.* 1987; 64:801-808.
185. Verdin EM, Maratos-Flier E, Kahn CR, Sodoyez JC, Sodoyez-Goffaux F, DeVos CJ, Lynn SP, Fields BN. Visualization of viral clearance in the living animal. *Science.* 1987; 236:439-442.
186. Goren HJ, White MF, Kahn CR. Separate domains of the insulin receptor contain sites of autophosphorylation and tyrosine kinase activity. *Biochemistry.* 1987; 26:2374-2382.

187. White MF, Stegmann EW, Dull TS, Ullrich A, Kahn CR. Characterization of an endogenous substrate of the insulin receptor in cultured cells. *J Biol Chem.* 1987; 262:9769-9777.
188. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile diabetes mellitus. *Am J Cardiol.* 1987; 59:750-755.
189. Carpentier JL, White MF, Orci L, Kahn CR. Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. *J Cell Biol.* 1987; 105:2751-2762.
190. Goldstein BJ, Muller-Wieland D, Kahn CR. Variation in insulin receptor mRNA expression in human and rodent tissues. *Mol Endocrinol.* 1987; 1:759-766.
191. Beguinot F, Condorelli G, Kahn CR. The use of anti-receptor antibodies in studying insulin receptor. *Folia Allergol Immunol Clin.* 1987; 34:39-46.
192. Crettaz M, Muller-Wieland D, Kahn CR. Transcriptional and post-transcriptional regulation of tyrosine aminotransferase by insulin in rat hepatoma cells. *Biochemistry.* 1988; 27:495-500.
193. White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the  $\beta$ -subunit activates the phosphotransferase of the insulin receptor. *J Biol Chem.* 1988; 263:2969-2980.
194. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. *J Biol Chem.* 1988; 263:3440-3447
195. Shoelson SE, White MF, Kahn CR. Tryptic activation of the insulin receptor: Proteolytic truncation of the  $\alpha$ -subunit releases the  $\beta$ -subunit from inhibitory control. *J Biol Chem.* 1988; 263:4852-4860.
196. Okamoto M, Kahn CR, Maron R, White MF. Decreased autophosphorylation of EGF receptor in insulin deficient diabetic rats. *Am J Physiol.* 1988; 254 (Endocrinol. Metab. 17):E429-E434.
197. Beguinot F, Smith RJ, Kahn CR, Maron R, Moses AC, White MF. Phosphorylation of the insulin-like growth factor-I receptor by the insulin receptor tyrosine kinase in intact cultured skeletal muscle cells. *J Biol Chem.* 1988; 27:3222-3228.
198. Ludwig S, Muller-Wieland D, Goldstein BJ, Kahn CR. The insulin receptor gene and its expression in insulin-resistant mice. *Endocrinology.* 1988; 123:594-600.
199. Takayama S, Kahn CR, Kubo K, Foley JE. Alterations in insulin receptor autophosphorylation in insulin resistance: Correlation with altered sensitivity to glucose transport and anti-lipolysis to insulin. *J Clin Endocrinol Metab.* 1988; 66:992-999.

200. Vlachokosta FV, Piper CM, Gleason R, Kinzel L, Kahn CR. Dietary carbohydrate, a Big Mac, and insulin requirements in Type I diabetes. *Diabetes Care*. 1988; 11:330-336.
201. Karasik A, Pepinsky RB, Shoelson SE, Kahn CR. Lipocortins 1 and 2 as substances for the insulin receptor kinase in rat liver. *J Biol Chem*. 1988; 263:11862-11867.
202. Goldstein BJ, Kahn CR. Initial processing of the insulin receptor precursor in vivo and in vitro. *J Biol Chem*. 1988; 263:12809-12812.
203. Rothenberg PL, Kahn CR. Insulin inhibits pertussis-toxin catalyzed ADP-ribosylation of G-Proteins. *J Biol Chem*. 1988; 263:15546-15552.
204. Kriauciunas KM, Kahn CR, Muller-Wieland D, Reddy SS, Taub R. Altered expression and function of the insulin receptor in a family with lipotrophic diabetes. *J Clin Endocrinol Metab*. 1988; 67:1284-1293.
205. White MF, Livingston JN, Backer JM, Lauris V, Dull TJ, Ullrich A, Kahn CR. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. *Cell*. 1988; 54:641-649.
206. Karasik A, Kahn CR. Dexamethasone-induced changes in phosphorylation of the insulin and EGF receptors and their substrates in intact rat hepatocytes. *Endocrinology*. 1988; 123:2214-2222.
207. Reddy SS, Lauris V, Kahn CR. Insulin receptor function in fibroblasts from patients with leprechaunism: Differential alterations in binding, autophosphorylation, kinase activity and receptor mediated internalization. *J Clin Invest*. 1988; 82:1359-1365.
208. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. *J Clin Invest*. 1988; 82:1151-1156.
209. Cox NJ, Spielman RS, Kahn CR, Muller-Wieland D, Kriauciunas KM, Taub R. Four RFLPs of the human insulin receptor gene: PstI, RsaI(2), KpnI. *Nucleic Acids Res*. 1988; 16:8204.
210. Reddy SSK, Kahn CR. Insulin resistance: A look at the role of insulin receptor kinase. *Diabetic Medicine*. 1988; 5:621-629.
211. Karasik A, Pepinsky RB, Kahn CR. Insulin and epidermal growth factor stimulate phosphorylation of a 170 kDa protein in intact hepatocytes immunologically related to lipocortin 1. *J Biol Chem*. 1988; 263:18558-18562.
212. Warram JH, Krolewski AS, Kahn CR. Determinants of IDDM and perinatal mortality in children of diabetic mothers. *Diabetes*. 1988; 37:1328-1334.
213. Sale EM, Fujita-Yamaguchi Y, Kahn CR. Insulin-dependent changes in phosphofructokinase activity on incubation of the enzyme with insulin receptor. *Biochem (Life Sci. Adv)*. 1988; 7:373-377.

214. Kwok CF, Goldstein BJ, Muller-Wieland D, Lee TS, Kahn CR, King GL. Identification of persistent defects in insulin receptor structure and function in capillary endothelial cells from diabetic BB rats. *J Clin Invest.* 1989; 83:127-136.
215. Muller-Wieland D, Taub R, Tewari DS, Kriauciunas KM, Reddy SS, Kahn CR. The insulin receptor gene and its expression in patients with insulin resistance. *Diabetes.* 1989; 38:31-38.
216. Backer JM, White MF, Kahn CR. Tyrosine phosphorylation of the insulin receptor during insulin stimulated internalization in rat hepatoma cells. *J Biol Chem.* 1989; 264:1694-1701.
217. Karasik A, O'Hara C, Srikanta S, Swift M, Soeldner JS, Kahn CR, Herskowitz RD. Genetically programmed selective islet  $\beta$ -cell loss in diabetic subjects with Wolfram's Syndrome. *Diabetes Care.* 1989; 12:135-138.
218. Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: Application to the insulin receptor. *Biochem Biophys Res Commun.* 1989; 159:664-669.
219. Kahn CR, Lauris V, Koch S, Crettaz M, Granner DJ. Acute and chronic regulation of phosphoenolpyruvate carboxykinase mRNA by insulin and glucose. *Mol Endocrinol.* 1989; 3:840-845.
220. Shoelson SE, White MF, Kahn CR. Non-phosphorylatable substrate analogs selectively block autophosphorylation and activation of the insulin receptor, EGF receptor and pp60<sup>v-src</sup> kinase. *J Biol Chem.* 1989; 264:7831-7836.
221. Perlman R, Bottaro DP, White MF, Kahn CR. Conformational changes in the  $\alpha$ - and  $\beta$ -subunits of the insulin receptor identified by anti-peptide antibodies. *J Biol Chem.* 1989; 264:8946-8950.
222. Cox NJ, Spielman RS, Kahn CR, Muller-Wieland D, Kriauciunas KM, Taub R. Four RFLPs of the human insulin receptor gene: PstI, RsaI(2), KpnI. *Nucleic Acids Res.* 1989; 17:820.
223. Goldstein BJ, Kahn CR. Insulin receptor messenger ribonucleic acid sequence alterations detected by ribonuclease cleavage in patients with syndromes of insulin resistance. *J Clin Endocrinol Metab.* 1989; 69:15-24.
224. Backer JM, Kahn CR, White MF. Tyrosine phosphorylation of the insulin receptor is not required for receptor internalization: Studies in 2,4-dinitrophenol-treated cells. *Proc Natl Acad Sci. USA* 1989; 86:3209-3213.
225. Kahn CR, Goldstein BJ. Molecular defects in insulin action. *Science.* 1989; 245:13.
226. Gross DJ, Halban PA, Kahn CR, Weir GC, Villa Komaroff L. Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory

- pathway in transfected AtT-20 cells. *Proc Natl Acad Sci. USA* 1989; 86:4107-4111.
227. Beguinot F, Kahn CR, Moses AC, White MF, Smith RJ. Differentiation-dependent phosphorylation of a 175,000 molecular weight protein in response to insulin and insulin-like growth factor-I in L6 skeletal muscle cells. *Endocrinology*. 1989; 125:1599-1605.
  228. Reddy SSK, Muller-Wieland D, Kriauciunas KM, Kahn CR. Molecular defects in the insulin receptor in patients with leprechaunism and in their parents. *J Lab Clin Med*. 1989; 114:165-170.
  229. Meyerovitch J, Backer JM, Kahn CR. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. *J Clin Invest*. 1989; 84:976-983.
  230. White MF, Kahn CR. Cascade of autophosphorylation in the  $\beta$ -subunit of the insulin receptor. *J Cell Biochem*. 1989; 39:429-441.
  231. Hurrell DG, Pedersen O, Kahn CR. Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. *Endocrinology*. 1989; 125:2454-2462.
  232. Reddy SSK, Kahn CR. Epidermal growth factor receptor defects in leprechaunism: A multiple growth factor-resistant syndrome. *J Clin Invest*. 1989; 84:1569-1576.
  233. Gross DJ, Villa-Komaroff L, Kahn CR, Weir GC, Halban PA. Deletion of a highly conserved tetrapeptide sequence of the proinsulin connecting peptide (C-peptide) inhibits proinsulin to insulin conversion by transfected pituitary corticotroph (AtT20) Cells. *J Biol Chem*. 1989; 264:21486-21490.
  234. Karasik A, Reddy SSK, Pepinsky RB, Brock T, Kahn CR. Augmented desensitization to EGF immediate actions: A novel mechanism for altered EGF growth response in mutant A431 cells. *J Cell Physiol*. 1990; 142:231-235.
  235. Meyerovitch J, Kahn CR, Shechter Y. A family of polypeptide substrates and inhibitors of insulin receptor kinase. *Biochemistry*. 1990; 29:3654-3660.
  236. Karasik A, Rothenberg PL, Yamada K, White MF, Kahn CR. Increased protein kinase C activity is linked to reduced insulin receptor autophosphorylation in liver of starved rats. *J Biol Chem*. 1990; 265:10226-10231.
  237. Edge ASB, Kahn CR, Spiro RG. Insulin receptor carbohydrate units contain poly-N-acetyllactosamine chains. *Endocrinology*. 1990; 127:1887-1895.
  238. Backer JM, Kahn CR, White MF. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. *J Biol Chem*. 1990; 265:14828-14835.
  239. Wilden PA, Backer JM, Kahn CR, Cahill DA, Schroeder GJ, White MF. The insulin receptor with phenylalanine replacing tyrosine 1146 provides evidence for separate signals regulating cellular metabolism and growth. *Proc Natl Acad Sci. USA* 1990; 87:3358-3362.

240. Kruszynska YT, Halban PA, Kahn CR, White MF. Activation of liver and muscle insulin receptor tyrosine kinase activity during in vivo insulin administration in rats. *Diabetologia*. 1990; 33:77-83.
241. Okamoto M, Karasik A, White MF, Kahn CR. Epidermal growth factor stimulated phosphorylation of a 120 kilodalton endogenous substrate protein in rat hepatocytes. *Biochemistry*. 1990; 29:9489-9494.
242. Backer JM, Kahn CR, Cahill DA, Ullrich A, White MF. Receptor-mediated internalization of insulin requires a 12 amino acid sequence in the juxtamembrane region of the insulin receptor  $\beta$ -subunit. *J Biol Chem*. 1990; 265:16450-16454.
243. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia are predictors of the risk of Type II diabetes in offspring of diabetic parents. *Ann Int Med*. 1990; 113:909-915.
244. Okamoto M, Karasik A, White MF, Kahn CR. Coordinate phosphorylation of the insulin receptor kinase and its 175,000 M<sub>r</sub> endogenous substrate in rat hepatocytes. *Diabetes*. 1991; 40:66-72.
245. Hauguel de Mouzon S, Kahn CR. Insulin-like growth factor receptor mediate biological effects in MDCK cells. *Mol Endocrinol*. 1991; 5:51-60.
246. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. *J Clin Invest*. 1991; 87:1286-1294.
247. Csermely P, Kahn CR. The 90-kDa heat shock protein (hsp-90) possesses an ATP binding site and autophosphorylating activity. *J Biol Chem*. 1991; 266:4943-4950.
248. Shoelson SE, Boni-Schnetzler M, Kahn CR, Pilch PF. Intramolecular autophosphorylation occurs within individual  $\beta$ -subunits of the insulin receptor. *Biochemistry*. 1991; 30:7740-7746.
249. Rothenberg PL, Lane WS, Backer JM, White MF, Kahn CR. Purification and partial sequence analysis of pp185, the major cellular substrate of the insulin receptor tyrosine kinase. *J Biol Chem*. 1991; 266:8302-8311.
250. Sun XJ, Rothenberg PL, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. The molecular structure of the insulin substrate IRS-1 defines a unique signal transduction protein. *Nature*. 1991; 352:73-77.
251. Ferber S, Gross DJ, Villa-Komaroff L, Danehy F, Vollenweider F, Meyer K, Loeken MR, Kahn CR, Halban PA. Heterogeneity of expression and secretion of native and mutant [Asp<sup>B10</sup>]insulin in AtT20 cells. *Mol Endocrinol*. 1991; 5:319-326.
252. Pedersen O, Kahn CR, Flier JS, Kahn BB. High fat feeding causes insulin resistance and

- a marked decrease in the expression of glucose transporters (Glut4) in fat cells of rats. *Endocrinology*. 1991; 129:771-777.
253. Backer JM, Schroeder GC, Kahn CR, Myers MG, Wilden PA, Cahill DA, White MF. Insulin stimulation of phosphatidylinositol 3 kinase activity maps to insulin regions required for endogenous substrate phosphorylation. *J Biol Chem*. 1992; 267:1367-1374.
  254. Hauguel deMouzon S, Csermely P, Zoppini G, Kahn CR. Quantitative dissociation between EGF effects on c-myc and c-fos gene expression, DNA synthesis, and epidermal growth factor tyrosine kinase activity. *J Cell Physiol*. 1992; 150:180-187.
  255. Zoppini G, Kahn CR. Effect of phospholipase treatment on insulin receptor signal transduction. *Diabetologia*. 1992; 35:109-115.
  256. Cheatham B, Kahn CR. Cys<sup>647</sup> in the insulin receptor is required for normal covalent interaction between  $\alpha$  and  $\beta$ -subunits and signal transduction. *J Biol Chem*. 1992; 267:7108-7115.
  257. Yamada K, Goncalves E, Kahn CR, Shoelson SE. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro. *J Biol Chem*. 1992; 267:12452-12461.
  258. Wilden PA, Siddle K, Haring E, Backer JM, White MF, Kahn CR. The role of insulin receptor kinase domain autophosphorylation in receptor-mediated activities: Analysis with insulin and anti-receptor antibodies. *J Biol Chem*. 1992; 267:13719-13727.
  259. Wilden PA, Kahn CR, Siddle K, White MF. Insulin receptor kinase domain autophosphorylation regulates receptor enzymatic functions. *J Biol Chem*. 1992; 267:16660-16668.
  260. Pedersen O, Kahn CR, Kahn BB. Divergent regulation of the GLUT1 and GLUT4 glucose transporter in isolated adipocytes from Zucker rats. *J Clin Invest*. 1992; 89:1964-1973.
  261. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of Type II diabetes mellitus: Results of a 25 year follow-up study. *Lancet*. 1992; 340:925-929.
  262. Goldstein BJ, Zhang WR, Hashimoto N, Kahn CR. Approaches to the molecular cloning of protein-tyrosine phosphatases in insulin-sensitive tissues. *Mol Cell Biochem*. 1992; 109:107-113.
  263. Folli F, Saad MJA, Backer JM, Kahn CR. Insulin stimulation of phosphatidylinositol 3-kinase activity and association with IRS-1 in liver and muscle of the intact rat. *J Biol Chem*. 1992; 267:22171-22177.
  264. Sun XJ, Miralpeix M, Myers MG, Jr., Glasheen EM, Backer JM, Kahn CR, White MF. Expression and function of insulin receptor substrate 1 in insulin signal transmission. *J*

- Biol Chem. 1992; 267:22662-22672.
265. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR. Regulation of insulin receptor substrate 1 in liver and muscle of animal models of insulin resistance. *J Clin Invest.* 1992; 90:1839-1849.
  266. Csermely P, Kahn CR. Insulin induces the phosphorylation of DNA-binding nuclear proteins including lamins in 3T3-F442A. *Biochemistry.* 1992; 31:9940-9946.
  267. Meyerovitch J, Backer JM, Csermely P, Shoelson SE, Kahn CR. Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells. *Biochemistry.* 1992; 31:10338-10344.
  268. Csermely P, Kajtar J, Hollosi M, Jalsovszky G, Holly S, Kahn CR, Gergely P, Jr., Soti C, Mihaly K, Somogyi J. ATP induces a conformational change in the 90 kDa heat shock protein (HSP-90). *J Biol Chem.* 1993; 268:1901-1907.
  269. Kriauciunas KM, Goldstein BJ, Lipes MA, Kahn CR. Modulation of expression of insulin and IGF-1 receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines. *J Cell Physiol.* 1993; 154:486-495.
  270. Csermely P, Schnaider T, Cheatham B, Olson MOJ, Kahn CR. Insulin induces the phosphorylation of nucleolin: A possible mechanism of insulin-induced RNA-efflux from nuclei. *J Biol Chem.* 1993; 268:9747-9752.
  271. Feener EP, Backer JM, King GL, Wilden PA, Sun X-J, Kahn CR, White MF. Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. *J Biol Chem.* 1993; 268:11256-11264.
  272. Chuang LM, Myers MG, Jr., Seidner GA, Birnbaum MJ, White MF, Kahn CR. Insulin receptor substrate-1 (IRS-1) mediates insulin and IGF-1 stimulated maturation of *Xenopus* oocytes. *Proc Natl Acad Sci. USA* 1993; 90:5172-5175.
  273. Araki E, Sun XJ, Haag BL, III, Chuang LM, Zhang Y, Yang-Feng TL, White MF, Kahn CR. Human skeletal muscle insulin receptor substrate (IRS-1): Characterization of the cDNA, gene and chromosomal localization. *Diabetes.* 1993; 42:1041-1054.
  274. Goncalves E, Yamada K, Thatte HS, Backer JM, Golan DE, Kahn CR, Shoelson SE. Optimizing transmembrane domain helicity accelerates insulin receptor internalization and lateral mobility. *Proc Natl Acad Sci. USA* 1993; 90:5762-5766.
  275. Cheatham B, Shoelson SE, Yamada K, Goncalves E, Kahn CR. Substitution of the neu oncprotein transmembrane domain activates the insulin receptor and modulates insulin's actions and IRS-1. *Proc Natl Acad Sci. USA* 1993; 90:7336-7340.
  276. Folli F, Saad MJA, Backer JM, Kahn CR. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin resistant and insulin deficient diabetes mellitus. *J Clin Invest.* 1993; 92:1787-1794.

277. Saad MJA, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1 (IRS-1) and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone treated rats. *J Clin Invest.* 1993; 92:2065-2072.
278. Kim SJ, Kahn CR. Insulin induces rapid accumulation of insulin receptors and increases tyrosine kinase activity in the nucleus of cultured adipocytes. *J Cell Physiol.* 1993; 157:217-228.
279. Reynet C, Kahn CR. Rad: A member of the Ras family overexpressed in muscle of Type II diabetic humans. *Science.* 1993; 262:1441-1444.
280. Carpentier JL, Paccaud JP, Backer J, Gilbert A, Orci L, Kahn CR. Two steps of insulin receptor internalization depend on different domains of the  $\beta$ -subunit. *J Cell Biol.* 1993; 122:1243-1252.
281. Chuang LM, Myers MG, Jr., Backer JM, Shoelson SE, White MF, Birnbaum MJ, Kahn CR. Insulin-stimulated oocyte maturation requires IRS-1 and interaction with the SH2 domains of phosphatidylinositol 3-kinase. *Mol Cell Biol.* 1993; 13:6653-6660.
282. Edge ASB, Karasik A, Yamada K, Kahn CR. Effect of dexamethasone on the carbohydrate chains of the insulin receptor. *Biochem Biophys Res Commun.* 1994; 200:852-859.
283. Kim SJ, Kahn CR. Insulin stimulates phosphorylation of c-Jun, c-Fos and Fos-related proteins in cultured adipocytes. *J Biol Chem.* 1994; 269:11887-11892.
284. Kahn CR. Picking a research problem: The critical decision. *N Engl J Med.* 1994; 330:1530-1533.
285. Araki E, Haag, III, BL, Kahn CR. Cloning of the mouse insulin receptor substrate-1 (IRS-1) gene and complete sequence of mouse IRS-1. *Biochim Biophys ACTA.* 1994; 1221:353-356.
286. Saad MJA, Folli F, Araki E, Hashimoto N, Csermely P, Kahn CR. Regulation of insulin receptor, insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-F442A adipocytes. Effects of differentiation, insulin, and dexamethasone. *Mol Endocrinol.* 1994; 8:545-557.
287. Wilden PA, Kahn CR. The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, MAP and S6 kinases. *Mol Endocrinol.* 1994; 8:558-567.
288. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. *Mol Cell Biol.* 1994; 14:4902-4911.
289. Kahn CR. Insulin action, diabetogenes, and the cause of Type II diabetes. (Banting Lecture) *Diabetes.* 1994; 43:1066-1084.

290. Ferber S, Meyerovitch J, Kriauciunas KM, Kahn CR. Vanadate normalizes hyperglycemia and PEPCK mRNA levels in ob/ob mice. *Metabolism*. 1994; 43:1346-1354.
291. Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. *J Neurosci*. 1994; 14:6412-6422.
292. Araki E, Lipes MA, Patti ME, Bruning JC, Haag BL, Johnson RS, Kahn CR. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. *Nature*. 1994; 372:186-190.
293. Chuang LM, Hausdorff SF, Myers MG, Jr., White MF, Birnbaum MJ, Kahn CR. Interactive roles of Ras, insulin receptor substrate-1, and proteins with Src homology-2 domains in insulin signaling in *Xenopus* oocytes. *J Biol Chem*. 1994; 269:27645-27649.
294. Alarcon C, Cheatham B, Lincoln B, Kahn CR, Siddle K, Rhodes CJ. A Kex2-related endopeptidase activity present in rat liver specifically processes the insulin proreceptor. *Biochem J*. 1994; 301:257-265.
295. Ouwens DM, van der Zon GCM, Pronk GJ, Bos JL, Moller W, Cheatham B, Kahn CR, Maassen JA. A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein 2 (Grb2) complex and p21<sup>ras</sup>-GTP without detectable interaction of insulin receptor substrate 1 (IRS1) with Grb2. Evidence for IRS1-independent p21<sup>ras</sup>-GTP formation. *J Biol Chem*. 1994; 269:33116-33122.
296. Yamada K, Goncalves E, Carpentier JL, Kahn CR, Shoelson SE. Transmembrane domain inversion blocks ER release and insulin receptor signaling. *Biochemistry*. 1995; 34:946-954.
297. Antonetti D, Reynet C, Kahn CR. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. *J Clin Invest*. 1995; 95:1383-1388.
298. Rothman DL, Magnusson I, Cline G, Gerard D, Kahn CR, Shulman RG, Shulman GI. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. *Proc Natl Acad Sci USA* 1995; 92:983-987.
299. Yamada K, Carpentier JL, Cheatham B, Goncalves E, Shoelson SE, Kahn CR. Role of transmembrane domain flanking amino acids in internalization and down-regulation of the insulin receptor. *J Biol Chem*. 1995; 270:3115-3122.
300. Zhu J, Reynet C, Caldwell JS, Kahn CR. Characterization of Rad, a new member of Ras/GTPase superfamily, and its regulation by a unique GAP-like activity. *J Biol Chem*. 1995; 270:4805-4812.
301. Saad MJA, Folli F, Kahn CR. Insulin and dexamethasone regulate insulin receptors, IRS-1 and phosphatidylinositol 3-kinase in Fao hepatoma cells. *Endocrinology* . 1995; 136:1579-1588.

302. Araki E, Haag III, BL, Matsuda K, Shichiri M, Kahn CR. Characterization and regulation of the mouse insulin receptor substrate gene promoter. *Mol Endocrinol.* 1995; 9:1367-1379.
303. Magre J, Goldfine AB, Warram JH, Krolewski AS, Kahn CR. Analysis of the insulin receptor gene in non-insulin dependent diabetes mellitus by denaturing gradient gel blots. *J Clin Endocrinol Metab.* 1995; 80:1882-1887
304. Doria A, Caldwell JS, Ji L, Reynet C, Rich SS, Weremowicz S, Morton CC, Warram JH, Kahn CR, Krolewski AS. Trinucleotide repeats at the rad locus: Allele distributions in NIDDM and mapping to a 3-cM region on chromosome 16q. *Diabetes.* 1995; 44:243-247.
305. Renard E, Grigorescu F, LaVabre C, Kahn CR. Insulin dependent phosphatidylinositol 3-kinase activity co-precipitates with insulin receptor in human circulating mononuclear cells. *Biochem Biophys Res Commun.* 1995; 209:234-241.
306. Patti ME, Sun XJ, Bruning JC, Araki E, Lipes MA, White MF, Kahn CR. 4PS/Insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. *J Biol Chem.* 1995; 270:24670-24673.
307. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. *J Clin Endocrinol Metab.* 1995; 80:3311-3320
308. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. *Mol Cell Biochem.* 1995; 153:217-231.
309. Myers MG, Jr, Cheatham B, Fisher TL, Jachna BR, Kahn CR, Backer JM, White MF. Common and distinct elements in insulin and PDGF signaling. *Ann NY Acad Sci.* 1995; 766:369-387.
310. Reynet C, Kahn CR, Loeken MR. Expression of the gene encoding glycogen phosphorylase is elevated in rat skeletal muscle and is regulated by insulin and cyclic AMP. *Diabetologia.* 1996; 39:183-189
311. Zhu J, Bilan PJ, Moyers JS, Antonetti DA, Kahn CR. Rad, a novel ras-related GTPase, interacts with skeletal muscle  $\beta$ -tropomyosin. *J Biol Chem.* 1996; 271:768-773.
312. Antonetti DA, Algenstaedt P, Kahn CR. Insulin receptor substrate-1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. *Mol Cell Biol.* 1996; 16:2195-2203.
313. Ura S, Araki E, Kishikawa H, Shirotani T, Todaka M, Isami S, Shimoda S, Yoshimura R, Matsuda K, Motoyoshi S, Miyamura N, Kahn CR, Shichiri M. Molecular scanning of the IRS-1 gene in Japanese patients with non-insulin-dependent diabetes mellitus: Identification of five novel polymorphisms in IRS-1 gene. *Diabetologia.* 1996; 39:600-

608.

314. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signalling: Evidence from transfection studies. *J Clin Invest.* 1996; 97:2569-2575.
315. Chuang LM, Tai TY, Kahn RC, Wu HP, Lee SC, Lin BJ. Signal transduction pathways for interleukin 4 and insulin in human hepatoma cells. *J Biochem.* 1996; 120:111-116.
316. Inoue G, Cheatham B, Kahn CR. Different pathways of post-receptor desensitization following chronic insulin treatment and in cells overexpressing constitutively active insulin receptors. *J Biol Chem.* 1996; 271:28206-28211.
317. Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. *Proc Natl Acad Sci. USA* 1996; 93:12490-12495.
318. Caldwell JS, Moyers JS, Doria A, Reynet C, Kahn CR. Molecular cloning of the human Rad gene: Gene structure and complete nucleotide sequence. *Biochim Biophys Acta.* 1996; 1316:145-148.
319. Moyers JS, Bilan PJ, Reynet C, Kahn CR. Overexpression of Rad inhibits glucose uptake in cultured muscle and fat cells. *J Biol Chem.* 1996; 271:23111-23116.
320. Cheatham B, Volchuk A, Kahn CR, Wang L, Rhodes CJ, Klip A. Functional role of synaptobrevins in insulin-stimulated translocation of GLUT4 glucose transporters. *Proc Natl Acad Sci. USA* 1996; 93:15169-15173.
321. Bruning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. *Mol Cell Biol.* 1997; 17:1513-1521.
322. Bruning J, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of non-insulin-dependent diabetes mellitus in mice heterozygous for insulin receptor and IRS-1 null alleles. *Cell.* 1997; 88:561-572.
323. Moyers JS, Bilan PJ, Zhu J, Kahn CR. Rad and Rad-related GTPases interact with calmodulin and calmodulin-dependent protein kinase II. *J Biol Chem.* 1997; 272:11832-11839.
324. Kim SJ, Kahn CR. Insulin stimulates p70 S6 kinase in the nucleus of cells. *Biochem Biophys Res Commun.* 1997; 234:681-685.
325. Smith-Hall J, Pons S, Patti ME, Burks DJ, Yenush L, Sun XJ, Kahn CR, White MF. The 60 kDa insulin receptor substrate functions like an IRS-protein (pp60<sup>IRS3</sup>) in adipose cells. *Biochemistry.* 1997; 36:8304-8310.
326. Kim SJ, Kahn CR. Insulin regulation of mitogen-activated protein kinase kinase (MEK) mitogen-activated protein kinase and casein kinase in the cell nucleus: A possible role in

- the regulation of gene expression. *Biochem J.* 1997; 323:621-627.
327. Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR. Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca<sup>2+</sup>-ATPases in muscle and heart. *J Biol Chem.* 1997; 272:23696-23702.
  328. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J Clin Invest.* 1997; 100:2158-2169.
  329. Zhu JW, Kahn CR. Analysis of a peptide hormone-receptor interaction in the yeast two-hybrid system. *Proc Natl Acad Sci. USA* 1997; 94:13063-13068.
  330. Folli F, Alvaro D, Gigliozzi A, Bassotti C, Kahn CR, Pontiroli AE, Capocaccia L, Jezequel AM, Benedetti A. Regulation of endocytic-transcytotic pathways and bile secretion by phosphatidylinositol 3-kinase. *Gastroenterology.* 1997; 113:954-965.
  331. Kerouz NJ, Horsch D, Pons S, Kahn CR. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. *J Clin Invest.* 1997; 100:3164-3172.
  332. Emkey R, Kahn CR. Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes. I. Activation of protein kinase C stimulates tyrosine phosphorylation and activation of ErbB2 and ErbB3. *J Biol Chem.* 1997; 272:31172-31181.
  333. Emkey R, Kahn CR. Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes. II. Comparison of phorbol ester and sphingomyelinase-induced phosphorylation of ErbB2 and ErbB3. *J Biol Chem.* 1997; 272:31182-31189.
  334. Silver K, Walston J, Plotnick L, Taylor SI, Kahn CR, Shuldiner AR. Molecular scanning of the  $\beta$ 3-adrenergic receptor gene in total congenital lipoatrophic diabetes mellitus. *J Clin Endocrinol Metab.* 1997; 82:3395-3398.
  335. Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. *J Clin Invest.* 1998; 101:1519-1529.
  336. Ristow M, Giannakidou E, Hebinck J, Busch K, Vorgerd M, Kotzka J, Knebel B, Mueller-Berghaus J, Epplen C, Pfeiffer A, Kahn CR, Doria A, Krone W, Mueller-Wieland D. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/Frataxin (Friedreich's ataxia) gene. *Diabetes.* 1998; 47:851-854.
  337. Inoue G, Cheatham B, Emkey R, Kahn CR. Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. *J Biol Chem.* 1998; 273:11548-11555.
  338. Bilan PJ, Moyers JS, Kahn CR. The Ras-related protein Rad associates with the cytoskeleton in a non-lipid-dependent manner. *Exp Cell Res.* 1998; 242:391-400.

339. Vicent D, Piper M, Gammeltoft S, Maratos-Flier E, Kahn CR. Alterations in skeletal muscle gene expression of ob/ob mice by mRNA differential display. *Diabetes*. 1998; 47:1451-1458.
340. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. *N Engl J Med*. 1998; 339:953-959.
341. Brüning JC, Michael MD, Winnay JN, Hayashi T, Hörsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. *Mol Cell*. 1998; 2:559-569.
342. Moyers JS, Zhu J, Kahn CR. Effects of phosphorylation on function of the Rad GTPase. *Biochem J*. 1998; 333:609-614.
343. Wang J, Wilhelmsson H, Graff C, Li H, Oldfors A, Rustin R, Bruning J, Kahn CR, Clayton DA, Barsh GS, Thoren P, Larsson NG. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. *Nature Genetics*. 1999; 21:133-137.
344. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta-cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell*. 1999; 96:329-339.
345. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. *Exp Clin Endocrinol Diabetes*. 1999;107:133-139.
346. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. *J Clin Invest*. 1999; 103:931-943.
347. Hörsch D, Kahn CR. Region-specific mRNA expression of phosphatidylinositol 3-kinase regulatory isoforms in the central nervous system of C57BL/6J mice. *J Comp Neurol*. 1999; 415:105-120.
348. Wojtaszewski JF, Higaki Y, Hirshman MF, Michael MD, Dufresne SD, Kahn CR, Goodyear LJ. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. *J Clin Invest*. 1999; 104:1257-1264.
349. Pete G, Fuller CR, Oldham JM, Smith DR, D'Ercole AJ, Kahn CR, Lund PK. Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice. *Endocrinology*. 1999; 140:5478-5487.
350. Zhu J, Tseng YH, Kantor JD, Rhodes CJ, Zetter BR, Moyers JS, Kahn CR. Interaction of the Ras-related protein associated with diabetes rad and the putative tumor metastasis suppressor NM23 provides a novel mechanism of GTPase regulation. *Proc Natl Acad Sci USA* 1999; 96:14911-14918.
351. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, Kahn CR.

- Altered function of insulin receptor substrate-1-deficient mouse islets and cultured  $\beta$ -cell lines. *J Clin Invest.* 1999; 104: R69-R75.
352. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR. Beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. *J Biol Chem.* 1999; 274:34795-802.
  353. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. *Diabetes.* 1999; 48:1562-1571.
  354. Gazdag AC, Dumke CL, Kahn CR, Cartee GD. Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. *Diabetes.* 1999; 48:1930-1936.
  355. Inoue G, Cheatham B, Kahn CR. Development of an in vitro reconstitution assay for glucose transporter 4 translocation. *Proc Natl Acad Sci USA.* 1999; 96: 14919-14924.
  356. Valverde AM, Kahn CR, Benito M. Insulin signaling in insulin receptor substrate (IRS)-1-deficient brown adipocytes: requirement of IRS-1 for lipid synthesis. *Diabetes.* 1999; 48: 2122-31.
  357. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, Accili D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. *J Clin Invest.* 2000; 105:199-205.
  358. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawat T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *J Clin Invest.* 2000; 105:311-320.
  359. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. *Metabolism.* 2000; 49: 400-410.
  360. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. *Proc Natl Acad Sci USA.* 2000; 97: 2355-2360.
  361. Vicent D, Maratos-Flier E, Kahn CR. The branch point enzyme of the mevalonate pathway for protein prenylation is over expressed in the ob/ob mouse and induced by adipogenesis. *Mol Cell Biol.* 2000; 20:2158-2166.
  362. Winnay JN, Bruning JC, Burks DJ, Kahn CR. Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts. *J Biol Chem.* 2000; 275:10545-10550.
  363. Bruning JC, Gillette JA, Zhao Y, Bjorbaeck C, Kotzka J, Knebel B, Avci H, Hanstein B, Lingohr P, Moller DE, Krone W, Kahn CR, Muller-Wieland D. Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene. *Proc Natl Acad Sci USA.* 2000; 97: 2462-2467.

364. Kahn CR. Triglycerides and toggling the tummy. *Nat Genet.* 2000; 25:6-7.
365. Kahn CR, Rafferty JF. The Joslin Diabetes Center. *Mol Med.* 2000; 6:65-68.
366. Klein J, Fasshauer M, Benito M, Kahn CR. Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. *Mol Endocrinol.* 2000; 14:764-773.
367. Aspinwall CA, Qian WJ, Roper MG, Kulkarni RN, Kahn CR, Kennedy RT. Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular  $Ca^{2+}$  stores in insulin-stimulated insulin secretion in beta-cells. *J Biol Chem.* 2000; 275:22331-22338.
368. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell.* 2000; 6:87-97.
369. Bruning JC, Gautam DC, Burks DJ, Gillette J, Schubert M, Orban P, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. *Science.* 2000 ;289:2122-2125.
370. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. *Mol Cell Biol.* 2000;20:8035-8046.
371. Hebinck J, Hardt C, Schols L, Vorgerd M, Briedigkeit L, Kahn CR, Ristow M. Heterozygous expansion of the GAA tract of the X25/frataxin gene is associated with insulin resistance in humans. *Diabetes.* 2000; 49:1604-1607.
372. Kriauciunas KM, Myers MG Jr, Kahn CR. Cellular compartmentalization in insulin action: altered signaling by a lipid-modified IRS-1. *Mol Cell Biol.* 2000; 20:6849-6859.
373. Fasshauer M, Klein J, Ueki K, Kriauciunas KM, Benito M, White MF, Kahn CR. Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. *J Biol Chem.* 2000; 275:25494-25501.
374. Ristow M, Pfister MF, Yee AJ, Schubert M, Michael L, Zhang CY, Ueki K, Michael MD II, Lowell BB, Kahn CR. Frataxin activates mitochondrial energy conservation and oxidative phosphorylation. *Proc Natl Acad Sci. USA* 2000; 97:12239-12243.
375. Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, Lowell BB, Wojtaszewski JF, Hirshman MF, Virkamaki A, Goodyear LJ, Kahn CR, Kahn BB. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. *Nat Med.* 2000; 6:924-928.
376. Mauvais-Jarvis F, Virkamaki A, Michael MD, Winnay JN, Zisman A, Kulkarni RN, Kahn CR. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. *Diabetes.* 2000; 49:2126-

- 2134.
377. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. *J Clin Invest.* 2000; 106:1305-1307.
  378. Mauvais-Jarvis F, Kahn CR. Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic knockout mice? *Diabetes Metab.* 2000; 26:433-448.
  379. Kim JK, Zisman A, Peroni OD, Kim YB, Perret P, Kahn CR, Kahn BB, Shulman GI. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. *J Biol Chem.* 2000; 275:8456-8460.
  380. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. *J Clin Invest.* 2000;105: 1791-7.
  381. Kahn CR. Dissecting the Genetics of Type 2 Diabetes: Stories of Mice and Men, *Emirates Medical Journal.* 2000;18(3 suppl.):29-35.
  382. Tseng YH, Vicent D, Zhu J, Niu Y, Adeyinka A, Moyers JS, Watson PH, Kahn CR. Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23. *Cancer Res.* 2001; 61:2071-2079.
  383. Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn CR, de Vargas LM, Berggren PO. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. *Mol Cell.* 2001; 7:559-570.
  384. Valverde AM, Mur C, Pons S, Alvarez AM, White MF, Kahn CR, Benito M. Association of insulin receptor substrate 1 (IRS-1) Y895 with Grb-2 mediates the insulin signaling involved in IRS-1-deficient brown adipocyte mitogenesis. *Mol Cell Biol.* 2001; 21:2269-2280.
  385. Reynet C, Kahn CR. Unbalanced expression of the different subunits of elongation factor 1 in diabetic skeletal muscle. *Proc Natl Acad Sci. USA* 2001; 98:3422-3427.
  386. Almind K, Doria A, Kahn CR. Putting the genes for type II diabetes on the map. *Nat Med.* 2001; 7:277-279.
  387. Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M, Kahn CR. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. *Mol Cell Biol.* 2001; 21:319-329.
  388. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K, Kahn CR. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1-and IRS-2-mediated signaling. *Mol Cell Biol.* 2001; 21:26-38.

389. Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. *Proc Natl Acad Sci USA*. 2001; 98:7475-80.
390. Kim JK, Zisman A, Fillmore JJ, Peroni OD, Kotani K, Perret P, Zong H, Dong J, Kahn CR, Kahn BB, Shulman GI. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. *J Clin Invest*. 2001; 108:153-160.
391. Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr, Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Bachy A, Verloes A, d'Abronzio FH, Seemanova E, Assan R, Baudic N, Bourut C, Czernichow P, Huet F, Grigorescu F, de Kerdanet M, Lacombe D, Labrune P, Lanza M, Loret H, Matsuda F, Navarro J, Nivelon-Chevalier A, Polak M, Robert JJ, Tric P, Tubiana-Rufi N, Vigouroux C, Weissenbach J, Savasta S, Maassen JA, Trygstad O, Bogalho P, Freitas P, Medina JL, Bonnicci F, Joffe BI, Loyson G, Panz VR, Raal FJ, O'Rahilly S, Stephenson T, Kahn CR, Lathrop M, Capeau J. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. *Nat Genet*. 2001; 28:365-370.
392. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature*. 2001; 413:125-126.
393. Guerra C, Navarro P, Valverde AM, Arribas M, Bruning J, Kozak LP, Kahn CR, Benito M. Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. *J Clin Invest*. 2001; 108:1205-13.
394. Dumke CL, Wetter AC, Arias EB, Kahn CR, Cartee GD. Absence of insulin receptor substrate-1 expression does not alter glut1 or glut4 abundance or contraction-stimulated glucose uptake by mouse skeletal muscle. *Horm Metab Res*. 2001; 12:696-700.
395. Almind K, Delahaye L, Hansen T, Van Obberghen E, Pedersen O, Kahn CR. The Met326Ile variant of phosphatidylinositol 3-kinase p85 $\alpha$  has altered expression and interaction with IRS-1. *PROC NATL ACAD SCI U S A*. 2001; 1-5.
396. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC. Increased insulin sensitivity in mice lacking p85 $\beta$  subunit of phosphoinositide 3-kinase. *PROC NATL ACAD SCI U S A*. 2002; 99:419-424.
397. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. *Science*. 2002; 295:140-143.
398. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85 subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. *J Clin Invest*. 2002; 109:141-149.

399. Ueki K, Fruman DA, Brachmann SM, Tseng Y-H, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. *Mol Cell Biol.* 2002; 22:965-977.
400. Shoichet SA, Baumer AT, Stamenkovic D, Sauer H, Pfeiffer AFH, Kahn CR, Muller-Wieland D, Richter C, Ristow M. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation *in vitro*. *Human Mol Gen.* 2002;11:815-821.
401. Klein J, Fasshauer M, Klein HH, Benito M, Kahn CR. Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. *BioEssays* 2002; 24:382-388.
402. Kulkarni RN, Holzenberger M, Shih DQ, Ozcan U, Stoffel M, Magnuson MA, Kahn CR.  $\beta$ -cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter  $\beta$ -cell mass. *Nature Genetics* 2002; 31:111-115.
403. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. *Develop Cell* 2002; 3:1-14.
404. Jost P, Fasshauer M, Kahn CR, Benito M, Meyer M, Ott V, Lowell BB, Klein HH, Klein J. Atypical  $\beta$ -adrenergic effects on insulin signaling and action in  $\beta_3$ -adrenoceptor-deficient brown adipocytes. *Am J Physiol Endocrinol Metab* 2002; 283:E146-E153.
405. Hamer I, Foti M, Emkey R, Cordier-Bussat M, Philippe J, De Meyts P, Maeder C, Kahn CR, Carpentier J-L. An arginine to cysteine 252 mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalization but preserves signaling events. *Diabetologia* 2002; 45:657-667.
406. Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. *Proc Natl Acad Sci USA* 2002; 99:10587-10592.
407. Crackower M, Oudit G, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng H, Rybin V, Lembo G, Fratta L, Oliveira-dos-Santos A, Benovic J, Kahn C, Izumo S, Steinberg S, Wymann M, Backx P, Penninger J. Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways. *Cell* 2002; 110:737
408. Tseng Y-H, Ueki K, Kriauciunas KM, Kahn CR. Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin. *J Biol Chem* 2002; 277:31601-31611.
409. Maldergem LV, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. *J Med Genet* 2002; 39:722-733.

410. Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE, Kahn CR. Lipoatrophic diabetes in IRS1 (-/-)/IRS3(-/-) double knockout mice. *Genes Dev.* 2002; 24:3213-3222.
411. Mauvais-Jarvis F, Kulkarni RN, Kahn CR. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. *Clin Endocrinol (Oxf)* 2002; 1:1-9.
412. Roper MG, Qian WJ, Zhang BB, Kulkarni RN, Kahn CR, Kennedy RT. Effect of the insulin mimetic L-783,281 on intracellular  $Ca^{2+}$  and insulin secretion from pancreatic beta-cells. *Diabetes* 2002 Suppl 1:S43-39.
413. Kahn CR. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice. *The Gordon Wilson Lecture: American Clinical and Climatological Association Vol 114. The Kingsmill Resort, Williamsburg, Virginia, October 24-27, 2002.*
414. Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE, Kahn CR. Lipoatrophic diabetes in *Irs1(-/-)/Irs3(-/-)* double knockout mice. *Genes Dev.* 2002 Dec 15;16(24):3213-22.
415. Hamer I, Foti M, Emkey R, Cordier-Bussat M, Philippe J, De Meyts P, Maeder C, Kahn CR, Carpentier JL. An arginine to cysteine(252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events. *Diabetologia.* 2002 May;45(5):657-67.
416. Roper MG, Qian WJ, Zhang BB, Kulkarni RN, Kahn CR, Kennedy RT. Effect of the insulin mimetic L-783,281 on intracellular  $Ca^{2+}$  and insulin secretion from pancreatic beta-cells. *Diabetes.* 2002 Feb;51 Suppl 1:S43-9.
417. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science.* 2003; 299:572-574.
418. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. *J Clin Invest* 2003 Feb 15;111(4):463-468.
419. Vicent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki Y, Bursell S, Masashi Y, King GL, Kahn CR. The Role of Endothelial Insulin Signaling in the Regulation of Vascular Tone and Insulin Resistance. *J Clin Invest.* 2003; 1373-1380.
420. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR. Knockout of Insulin and Insulin-like Growth Factor 1 Receptors on Vascular Endothelial Cells Protects Against Retinal Neovascularization. *J Clin Invest* 2003;111(12) 1835-1842.
421. Lee AV, Zhang P, Ivanova M, Bonnette S, Oesterreich S, Rosen JM, Grimm S, Hovey RC, Vonderhaar BK, Kahn CR, Torres D, George J, Mohsin S, Allred DC, Hadsell DL. Developmental and hormonal signals dramatically alter the localization and abundance of

- insulin receptor substrate proteins in the mammary gland. *Endocrinology* 2003 Jun;144(6):2683-94.
422. Goldfine AB, Bouche C, Parker RA, Kim C, Kerivan A, Soeldner JS, Martin BC, Warram JH, Kahn CR. Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. *Proc Natl Acad Sci U S A* 2003 Mar 4;100(5):2724-9.
423. Valverde AM, Arribas M, Mur C, Navarro P, Pons S, Cassard-Doulier AM, Kahn CR, Benito M. Insulin-induced up-regulated uncoupling protein-1 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in fetal brown adipocytes. *J Biol Chem* 2003 Mar 21;278(12):10221-31.
424. Hallmann D, Trumper K, Trusheim H, Ueki K, Kahn CR, Cantley LC, Fruman DA, Horsch D. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. *J Biol Chem* 2003 Feb 14;278(7):5099-108.
425. Almind K, Kulkarni RN, Lannon SM, Kahn CR. Identification of interactive loci linked to insulin and leptin in mice with genetic insulin resistance. *Diabetes*. 2003 Jun;52(6):1535-43.
426. Kulkarni RN, Almind K, Goren HJ, Winnay JN, Ueki K, Okada T, Kahn CR. Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. *Diabetes*. 2003 Jun;52(6):1528-34.
427. Magrè J, et al. Brief Genetics Report: Prevalence of Mutations in AGPAT2 Among Human Lipodystrophies. *Diabetes*. 2003 Jun;52:1573-1578.
428. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR, King GL. Characterization of insulin's multiple signaling pathways in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. *J Biol Chem* 2003 May 29.
429. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. *Proc Natl Acad Sci U S A*. 2003 Jul 8;100(14):8466-71. Epub 2003 Jun 27.
430. Mora A, Davies AM, Bertrand L, Sharif I, Budas GR, Jovanovic S, Mouton V, Kahn CR, Lucocq JM, Gray GA, Jovanovic A, Alessi DR. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. *EMBO J*. 2003 Sep 15;22(18):4666-76.
431. Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. *Lancet*. 2003 Nov 1;362(9394):1431-2.
432. Entingh AJ, Taniguchi CM, Kahn CR. Bi-directional regulation of brown fat adipogenesis by the insulin receptor. *J Biol Chem*. 2003 Aug 29;278(35):33377-83.

433. Kahn, CR. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Albert Renold Memorial Lecture. *Experimental Diab Res* 2003;169-182.
434. Hirashima Y, Tsuruzoe K, Kodama S, Igata M, Toyonaga T, Ueki K, Kahn CR, Araki E. Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. *J Endocrinol.* 2003 Nov;179(2):253-66.
435. Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. *Cancer Res.* 2003 Sep 15;63(18):5850-8.
436. Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. *Mol Cell Biol.* 2003 Oct;23(20):7222-9.
437. Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. *J Biol Chem.* 2003 Nov 28;278(48):48453-66.
438. Wolfrum C, Shih DQ, Kuwajima S, Norris AW, Kahn CR, Stoffel M. Role of Foxa-2 in adipocyte metabolism and differentiation. *J Clin Invest.* 2003 Aug;112(3):345-56.
439. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. *J Clin Invest* 2003;112:608-618.
440. Minokoshi Y, Kahn CR, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. *J Biol Chem.* 2003 Sep 5;278(36):33609-12.
441. Burcelin R, Crivelli V, Perrin C, Da Costa A, Mu J, Kahn BB, Birnbaum MJ, Kahn CR, Vollenweider P, Thorens B. GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. *J Clin Invest.* 2003 May;111(10):1555-62.
442. Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. *Annu Rev Physiol.* 2003;65:313-32.
443. Chen D, Mauvais-Jarvis F, Bluher M, Fisher SJ, Jozsi A, Goodyear LJ, Ueki K, Kahn CR. p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. *Mol Cell Biol.* 2004 Jan;24(1):320-9.
444. Otani K, Kulkarni RN, Baldwin AC, Krutzfeldt J, Ueki K, Stoffel M, Kahn CR, Polonsky KS. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. *Am J Physiol Endocrinol Metab.* 2004 Jan;286(1):E41-E49.

445. Kulkarni RN, Kahn CR. Molecular biology. HNFs--linking the liver and pancreatic islets in diabetes. *Science*. 2004 Feb 27;303(5662):1311-2.
446. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC. Role for neuronal insulin resistance in neurodegenerative diseases. *Proc Natl Acad Sci U S A*. 2004 Mar 2;101(9):3100-5.
447. Tseng YH, Kriauciunas KM, Kokkotou E, Kahn CR. Differential roles of insulin receptor substrates in brown adipocyte differentiation. *Mol Cell Biol*. 2004 Mar;24(5):1918-29.
448. Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Succi ND, Friedman JM. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. *J Clin Invest*. 2004 Feb;113(3):414-24.
449. Cohen SE, Tseng YH, Michael MD, Kahn CR. Effects of insulin-sensitising agents in mice with hepatic insulin resistance. *Diabetologia*. 2004 Mar;47(3):407-11.
450. Kitamura T, Kitamura Y, Nakae J, Giordano A, Cinti S, Kahn CR, Efstratiadis A, Accili D. Mosaic analysis of insulin receptor function. *J Clin Invest*. 2004 Jan; 113(2): 209-19.
451. Cariou B, Postic C, Boudou P, Burcelin R, Kahn CR, Girard J, Burnol AF, Mauvais-Jarvis F. Cellular and Molecular Mechanisms of Adipose Tissue Plasticity in Muscle Insulin Receptor Knockout Mice. *Endocrinology*. 2004 Apr;145(4):1926-32.
452. Kondo T, Hafezi-Moghadam A, Thomas K, Wagner DD, Kahn CR. Mice lacking insulin of insulin-like growth factor 1 receptors in vascular endothelial cells maintain normal blood-brain barrier. *Biochem and Biophys Res Comm*. 2004; 317 (2):315-320.
453. Nandi A, Kitamura Y, Kahn CR, Accili D. Mouse models of insulin resistance. *Physiol Rev*. 2004 Apr;84(2):623-47.
454. Goren HJ, Kulkarni RN, Kahn CR. Glucose homeostasis and tissue transcript content of insulin signaling intermediates in four inbred strains of mice: C57BL/6, C57BLKS/6, DBA/2, and 129X1. *Endocrinology*. 2004 Jul;145(7):3307-23.
455. Bluher M, Wilson-Fritch L, Leszyk J, Laustsen PG, Corvera S, Kahn CR. Role of insulin action and cell size on protein expression patterns in adipocytes. *J Biol Chem*. 2004 Jul 23;279(30):31902-9.
456. Bluher M, Patti ME, Gesta S, Kahn BB, Kahn CR. Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knockout mice is associated with differences in patterns of gene expression. *J Biol Chem*. 2004 Jul 23;279(30):31891-901.
457. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. *Mol Cell Biol*. 2004 Jun;24(12):5434-46.
458. Kondo T, Kahn CR. Altered insulin signaling in retinal tissue in diabetic states. *J Biol Chem*. 2004 Sep 3;279(36):37997-8006.

459. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. *Proc Natl Acad Sci U S A*. 2004 Jul 13;101(28):10422-7.
460. Entingh-Pearsall A, Kahn CR. Differential roles of the insulin and insulin-like growth factor-I receptors in response to insulin and IGF-I. *J Biol Chem*. 2004 Sep 3;279(36):38016-24.
461. Mason SD, Howlett RA, Kim MJ, Olfert IM, Hogan MC, McNulty W, Hickey RP, Wagner PD, Kahn CR, Giordano FJ, Johnson RS. Loss of Skeletal Muscle HIF-1alpha Results in Altered Exercise Endurance. *PLoS Biol*. 2004 Aug 24;2(10):E288.
462. Bouché, C, Serdy, S, Kahn CR, Goldfine, AB. The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes. *Endocr Rev*. 2004 Oct;25(5):807-30.
463. Sajan MP, Standaert ML, Miura A, Kahn CR, Farese RV. Tissue-Specific Differences in Activation of Atypical Protein Kinase C and Protein Kinase B in Muscle, Liver and Adipocytes of Insulin Receptor Substrate-1 Knockout Mice. *Mol Endocrinol*. 2004 Oct;18(10):2513-21. Epub 2004 Jul 15.
464. Miura A, Sajan MP, Standaert ML, Bandyopadhyay G, Kahn CR, Farese RV. Insulin substrates 1 and 2 are corequired for activation of atypical protein kinase C and Cbl-dependent phosphatidylinositol 3-kinase during insulin action in immortalized brown adipocytes. *Biochemistry*. 2004 Dec 14;43(49):15503-9.
465. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. *J Clin Invest*. 2004 Sep;114(6):828-36.
466. Kahn CR, Roth J. Berson, Yalow, and the JCI: the agony and the ecstasy. *J Clin Invest*. 2004 Oct;114(8):1051-4.
467. Almind K, Kahn CR. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. *Diabetes*. 2004 Dec;53(12):3274-85.
468. Yechoor VK, Patti ME, Ueki K, Laustsen PG, Saccone R, Rauniyar R, Kahn CR. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. *Proc Natl Acad Sci U S A*. 2004 Nov 23;101(47):16525-30.
469. McGettrick AJ, Feener EP, Kahn CR. Human IRS-1 polymorphism, G972R, causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. *J Biol Chem*. 2005 Feb 25;280(8):6441-6.
470. Wijesekara N, Konrad D, Eweida M, Jefferies C, Liadis N, Giacca A, Crackower M, Suzuki A, Mak TW, Kahn CR, Klip A, Woo M. Muscle-Specific Pten Deletion Protects against Insulin Resistance and Diabetes. *Mol Cell Biol*. 2005 Feb;25(3):1135-45.
471. Fu M, Zhang J, Tseng YH, Cui T, Zhu X, Xiao Y, Mou Y, De Leon H, Chang MM, Hamamori Y, Kahn CR, Chen YE. Rad GTPase Attenuates Vascular Lesion Formation by Inhibition of Vascular Smooth Muscle Cell Migration. *Circulation*. 2005 Mar 1;111(8):1071-7.

472. Taniguchi CM, Ueki K, Kahn CR. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. *J Clin Invest.* 2005 Mar;115(3):718-27.
473. McGettrick AJ, Feener EP, Kahn CR. Human IRS-1 polymorphism, G972R, causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. *J Biol Chem.* 2005 Feb 25;280(8):6441-6.
474. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. *Mol Cell Biol.* 2005 Mar;25(5):1596-607.
475. Biddinger SB, Almind K, Miyazaki M, Kokkotou E, Ntambi JM, Kahn CR. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. *Diabetes.* 2005 May;54(5):1314-23.
476. Fisher S, Bruning JC, Lannon S, Kahn CR. Insulin signaling in central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. *Diabetes.* 2005 May;54(5):1447-51.
477. Tseng YH, Butte AJ, Kokkotou E, Yechoor VK, Taniguchi CM, Kriauciunas KM, Cypess AM, Niinobe M, Yoshikawa K, Patti ME, Kahn CR. Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and neclin. *Nat Cell Biol.* 2005 Jun;7(6):601-11. Epub 2005 May 15.
478. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, Roberson RS, Ricordi C, O'Connell PJ, Gonzalez FJ, Kahn CR. Loss of ARNT/HIF1beta Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes. *Cell.* 2005 Aug 12;122(3):337-49.
479. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M. Suppression of aging in mice by the hormone Klotho. *Science.* 2005 Sep 16;309(5742):1829-33.
480. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. Increased P85 {alpha} Is a Potent Negative Regulator of Skeletal Muscle Insulin Signaling and Induces in Vivo Insulin Resistance Associated with Growth Hormone Excess. *J Biol Chem.* 2005 Nov 11;280(45):37489-94.
481. Kim YB, Peroni OD, Aschenbach WG, Minokoshi Y, Kotani K, Zisman A, Kahn CR, Goodyear LJ, Kahn BB. Muscle-specific deletion of the Glut4 glucose transporter alters multiple regulatory steps in glycogen metabolism. *Mol Cell Biol.* 2005 Nov;25(21):9713-23.
482. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. *Hepatology Res.* 2005 Oct;33(2):185-92. Epub 2005 Oct 13.

483. Norris AW, Kahn CR Analysis of gene expression in pathophysiological states: Balancing false discovery and false negative rates. *Proc Natl Acad Sci U S A*. 2006 Jan 17;103(3):649-53.
484. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. *J Clin Invest*. 2005 Dec;115(12):3554-63.
485. Ilany J, Bilan PJ, Kapur S, Caldwell JS, Patti ME, Marette A, Kahn CR. Overexpression of Rad in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma triglyceride level. *Proc Natl Acad Sci U S A*. 2006 Mar 21;103(12):4481-6. Epub 2006 Mar 14.
486. He Z, Opland DM, Way KJ, Ueki K, Bodyak N, Kang PM, Izumo S, Kulkarni RN, Wang B, Liao R, Kahn CR, King GL. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. *Arterioscler Thromb Vasc Biol*. 2006 Apr;26(4):787-93. Epub 2006 Feb 9.
487. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKC $\lambda$ /zeta. *Cell Metab*. 2006 May;3(5):343-53.
488. Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, Peters JL, Shackman JG, Zhang M, Artner I, Satin LS, Stein R, Holzenberger M, Kennedy RT, Kahn CR, Kulkarni RN. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. *Nat Genet*. 2006 May;38(5):583-8. Epub 2006 Apr 23.
489. Gesta S, Bluher M, Yamamoto Y, Norris AW, Berndt J, Kralisch S, Boucher J, Lewis C, Kahn CR. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. *Proc Natl Acad Sci U S A*. 2006 Apr 25;103(17):6676-81. Epub 2006 Apr 14.
490. Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, Teshigawara K, Matsuki Y, Watanabe E, Hiramatsu R, Notohara K, Katayose K, Okamura H, Kahn CR, Noda T, Takeda K, Akira S, Inui A, Kasuga M. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. *Cell Metab*. 2006 Apr;3(4):267-75.
491. Baumgartl J, Baudler S, Scherner M, Babaev V, Makowski L, Suttles J, McDuffie M, Tobe K, Kadowaki T, Fazio S, Kahn CR, Hotamisligil GS, Krone W, Linton M, Bruning JC. Myeloid lineage cell-restricted insulin resistance protects apolipoprotein E-deficient mice against atherosclerosis. *Cell Metab*. 2006 Apr;3(4):247-56. Erratum in: *Cell Metab*. 2006 Jun;3(6):469. Tobe, Kazuyuki [added]; Kadowaki, Takashi [added].
492. Biddinger SB, Miyazaki M, Boucher J, Ntambi JM, Kahn CR. Leptin suppresses stearyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. *Diabetes*. 2006 Jul;55(7):2032-41.

493. Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC, Kahn CR. Phosphoinositide 3-kinase regulatory subunit p85 $\alpha$  suppresses insulin action via positive regulation of PTEN. *Proc Natl Acad Sci U S A*. 2006 Aug 8;103(32):12093-7. Epub 2006 Jul 31.
494. Koh HJ, Arnolds DE, Fujii N, Tran TT, Rogers MJ, Jessen N, Li Y, Liew CW, Ho RC, Hirshman MF, Kulkarni RN, Kahn CR, Goodyear LJ. Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. *Mol Cell Biol*. 2006 Nov;26(22):8217-27. Epub 2006 Sep 11.
495. Almind K, Manieri M, Sivitz WI, Cinti S, Kahn CR. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. *Proc Natl Acad Sci U S A*. 2007 Feb 13;104(7):2366-71. Epub 2007 Feb 5.
496. Laustsen PG, Russell SJ, Cui L, Entingh-Pearsall A, Holzenberger M, Liao R, Kahn CR. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. *Mol Cell Biol*. 2007 Mar;27(5):1649-64. Epub 2006 Dec 22.
497. Taniguchi CM, Aleman JO, Ueki K, Luo J, Asano T, Kaneto H, Stephanopoulos G, Cantley LC, Kahn CR. The p85 $\alpha$  Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance. *Mol Cell Biol*. 2007 Apr;27(8):2830-40. Epub 2007 Feb 5.
498. Mouche S, Mkaddem SB, Wang W, Katic M, Tseng YH, Carnesecchi S, Steger K, Foti M, Meier CA, Muzzin P, Kahn CR, Ogier-Denis E, Szanto I. Reduced expression of the NADPH oxidase NOX4 is a hallmark of adipocyte differentiation. *Biochim Biophys Acta*. 2007 Jul;1773(7):1015-27. Epub 2007 Mar 19.
499. Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, Xu C, Enriori P, Hampel B, Barsh GS, Kahn CR, Cowley MA, Ashcroft FM, Bruning JC. Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production. *Cell Metab*. 2007 Jun 6;5(6):438-449.
500. Xue B, Kim YB, Lee A, Toschi E, Bonner-Weir S, Kahn CR, Neel BG, Kahn BB. Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. *J Biol Chem*. 2007 Aug 17;282(33):23829-40. Epub 2007 Jun 1.
501. Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR Jr, Nimal S, Choi CS, Kim S, Shulman GI, Kahn CR, Braun U, Leitges M. Muscle-specific knockout of PKC- $\lambda$  impairs glucose transport and induces metabolic and diabetic syndromes. *J Clin Invest*. 2007 Aug;117(8):2289-301.
502. Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. *J Biol Chem*. 2007 Aug 10;282(32):23672-8. Epub 2007 Jun 7.

503. Bezy O, Vernochet C, Gesta S, Farmer SR, Kahn CR. TRB3 Blocks Adipocyte Differentiation through the Inhibition of C/EBPbeta Transcriptional Activity. *Mol Cell Biol.* 2007 Oct;27(19):6818-31. Epub 2007 Jul 23.
504. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. *Cell Metab.* 2007 Aug;6(2):105-14.
505. Fink BD, Herlein JA, Almind K, Cinti S, Kahn CR, Sivitz WI. Mitochondrial proton leak in obesity-resistant and obesity-prone mice. *Am J Physiol Regul Integr Comp Physiol.* 2007 Nov;293(5):R1173-80. Epub 2007 Aug 29.
506. Murata Y, Tsuruzoe K, Kawashima J, Furukawa N, Kondo T, Motoshima H, Igata M, Taketa K, Sasaki K, Kishikawa H, Kahn CR, Toyonaga T, Araki E. IRS-1 transgenic mice show increased epididymal fat mass and insulin resistance. *Biochem Biophys Res Commun.* 2007 Dec 14; 364(2):301-7. Epub 2007 Oct 12.
507. Gesta S, Tseng Y, Kahn CR. Developmental Origins of Fat: Tracking Obesity to its Source. *Cell.* 2007 Oct 19;131(2):242-56.
508. Pospilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, Ebersberger I, Nakashima T, Sarao R, Neely G, Esterbauer H, Kozlov A, Kahn CR, Kroemer G, Rustin P, Burcelin R, Penninger JM. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. *Cell.* 2007 Nov 2; 131(3):476-91.
509. Katic M, Kennedy AR, Leykin I, Norris A, McGettrick A, Gesta S, Russell SJ, Bluher M, Maratos-Flier E, Kahn CR. Mitochondrial gene expression and increased oxidative metabolism: role in increased lifespan of fat-specific insulin receptor knock-out mice. *Aging Cell.* 2007 Dec; 6(6):827-39.
510. Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. *Nat Clin Pract Endocrinol Metab.* 2007 Dec; 3(12):835-40.
511. Chang L, Zhang J, Tseng YH, Xie CQ, Ilany J, Bruning JC, Sun Z, Zhu X, Cui T, Youker KA, Yang Q, Day SM, Kahn CR, Chen YE. Rad GTPase deficiency leads to cardiac hypertrophy. *Circulation.* 2007 Dec 18; 116(25):2976-83. Epub 2007 Dec 3.
512. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Hass JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. *Cell Metab.* 2008 Feb;7(2):125-34.
513. Krüger M, Kratchmarova I, Blagoev B, Tseng YH, Kahn CR, Mann M. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. *Proc Natl Acad Sci U S A.* 2008 Feb 19;105(7):2451-6. Epub 2008 Feb 11.
514. Emanuelli B, Eberle D, Suzuki R, Kahn CR. Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. *Proc Natl Acad Sci U S A.* 2008 Mar 4;105(9):3545-50. Epub 2008 Feb 22.

515. Tiwari S, Sharma N, Gill P, Igarashi P, Kahn CR, Wade J, Ecelbarger K. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. *Proc Natl Acad Sci U S A*. 2008 Apr 29;105(17):6469-74. Epub 2008 Apr 18.
516. Tran T, Yamamoto Y, Gesta S, Kahn CR. Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism. *Cell Metab*. 2008 May 7; (5):410-20.
517. Kochl L, Wunderlich FT, Seibler J, Könnner AC, Hampel B, Irlenbusch S, Brabant G, Kahn CR, Schwenk F, Brüning JC. Central insulin action regulates peripheral glucose and fat metabolism in mice. *J Clin Invest*. 2008 Jun;118(6):2132-47.
518. Biddinger S, Hass JT, Yu BB, Bezy O, Jing E, Carey M, Kahn CR. Hepatic Insulin Resistance Directly Promotes Formation of Cholesterol Gallstones. *Nat Med*. 2008 Jul;14(7):778-82. Epub 2008 Jun 29.
519. Tseng Y, Kokkotou E, Huang TL, Taniguchi CM, Tran TT, Suzuki R, Schulz TJ, Espinoza DO, Winnay JN, Yamamoto Y, Ahrens MJ, Dudley AT, Norris AW, Kulkarni R, and Kahn CR. Novel role of bone morphogenetic protein-7 in brown adipogenesis and energy expenditure. *Nature*. 2008 Aug 21;454(7207):1000-4.
520. Princen F, Bard E, Sheikh F, Zhang SS, Wang J, Zago WM, Wu D, Diaz Trelles R, Bailly-Maitre B, Kahn CR, Chen Y, Reed JC, Tong GG, Mercola M, Chen J, Feng G. Deletion of Shp2 Tyrosine Phosphatase in Muscle Leads to Dilated Cardiomyopathy, Insulin Resistance and Premature Death. *Mol Cell Biol*. 2009 Jan;29(2):378-88 Epub 2008 Nov 10.
521. Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and Depot Differences in Adipocyte Insulin Sensitivity and Glucose Metabolism. *Diabetes*. 2009 Apr;58(4):803-12. Epub 2009 Jan 9.
522. Escribano O, Guillén C, Nevado C, Gómez-Hernández A, Kahn CR, Benito M. Beta-Cell Hyperplasia Induced by Hepatic Insulin Resistance: Role of a Live-Pancreatic Endocrine Axis Through Insulin Receptor A Isoform. *Diabetes*. 2009 Apr;58(4):820-8. Epub 2009 Jan 9.
523. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer Y, Tseng A, Doria A, Kolodny GM, Kahn CR. Identification and Physiologic Role of Brown Adipose Tissue in Human Adults. *New Engl. J. Med*. 2009 Apr 9;360(15):1509-17.
524. Wang XL, Suzuki R, Lee K, Tran T, Gunton JE, Saha AK, Patti ME, Goldfine A, Ruderman NB, Gonzalez FJ, Kahn CR. Ablation of ARNT/HIF1 $\beta$  in Liver Alters Gluconeogenesis, Lipogenic Gene Expression, and Serum Ketones. *Cell Metabolism*. 2009 May;9(5):428-39. Erratum in: *Cell Metab*. 2009 Jun;9(6):565.
525. Ristow M, Zarse K, Oberbach A, Klötting N, Birringer M, Kientopf M, Stumvoll M, Kahn CR, Bluher M. Antioxidants Prevent Anti-Diabetic and Health-Promoting Effects

of Physical Exercise. Proc Natl Acad Sci U S A. 2009 May 26;106(21):8665-70. Epub 2009 May 11.

526. Sajan MP, Standaert ML, Rivas J, Miura A, Kanoh Y, Soto J, Taniguchi CM, Kahn CR, Farese RV. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia. 2009 Jun; 52(6):1197-207. Epub 2009 Apr 9.
527. Ikeda H, Shiojima I, Ozasa Y, Yoshida M, Holzenberger M, Kahn CR, Walsh K, Igarashi T, Abel ED, Komuro I. Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced hypertrophy. J Mol Cell Cardiol. Epub 2009 Sept 7.
528. Sajan MP, Bandyopadhyay G, Miura A, Standaert M, Nimal S, Longnus SL, Van Obberghen E, Hainault I, Fougelle F, Kahn CR, Braun U, Leitges M, Farese RV. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK- and PDK1-dependent activation of atypical PKC. Am J Physiol Endocrinol Metab. Epub 2009 Nov 3.

## REVIEWS, CHAPTERS, EDITORIALS

1. Freychet P, Roth J, Kahn CR, Neville DM, Jr. Insulin-receptor interaction in the liver: Specific binding of  $^{125}\text{I}$ -insulin to the plasma membrane. In: INSERM, ed. Colloque sur les Hormones Pancreatiques, Vol. 1. Paris: 1972:335-357.
2. Gorden P, Roth J, Freychet P, Kahn CR. The circulating proinsulin-like components. *Diabetes*. 1972; 21:673-677.
3. Gorden P, Gavin JR, III, Kahn CR, Archer JA, Lesniak MA, Henricks CM, Neville DM, Jr., Roth J. Applications of radioreceptor assay to circulating insulin, growth hormone, and to their tissue receptors in animals and man. *Phar Rev*. 1973; 25:179-187.
4. Neville DM, Jr., Kahn CR, Soll AH, Roth J. Plasma membrane insulin receptor regulation by genetic, metabolic and hormonal factors. In: Peeters H, ed. *Protides of the biological fluids - 21st Colloquium*. New York: Pergamon Press, 1973:269-273.
5. Neville DM, Jr., Kahn CR. Isolation of plasma membranes for cell surface membrane receptor studies. In: Laskin AL, Last JA, eds. *Methods in molecular biology: Subcellular particles, structures and organelles*. Vol. 5 New York: Marcel Dekker Publisher, 1974:58-89.
6. Kahn CR. Membrane receptors for polypeptide hormones. In: Korn ED, ed. *Methods in membrane biology*, Vol 3. New York: Plenum Press, 1975:81-146.
7. Kahn CR, Soll AH, Neville DM, Jr., Goldfine ID, Archer JA, Gorden P, Roth J. The insulin receptor in obesity and other states of altered insulin sensitivity. In: *Obesity in perspective*, Fogarty International Center on Preventative Medicine, Col II, Part 2. United States Government Printing Office, Washington DC, 1975:301-311.
8. Kahn CR, Roth J. Cell membrane receptors for polypeptide hormones: Applications to the study of disease states in mice and man. *Am J Clin Pathol*. 1975; 63:656-668.
9. Roth J, Kahn CR, Lesniak MA, Gorden P, De Meyts P, Megyesi K, Neville DM, Jr., Gavin JR, III, Soll AH, Freychet P, Goldfine ID, Bar RS, Archer JA. Receptors for insulin, NSILA-s and growth hormone: Applications to disease states in man. *Recent Prog Horm Res*. 1975; 31:95-139.
10. Kahn CR, Roth J. Insulin receptors in disease states. In: Levey GS, ed. *Hormone-receptor interaction: Molecular aspects*. New York: Marcel Dekker, Inc., 1975:1-20.
11. Kahn CR. Insulin sensitivity and insulin resistance: Regulation of insulin receptors in vivo. In: Beers RL, Jr., Bassett EG, eds. *Cell membrane receptors for viruses, antigens and antibodies, polypeptide hormones and small molecules*. New York: Raven Press, 1976:33-46.
12. Kahn CR. Membrane receptors for hormones and neurotransmitters. *J Cell Biol*. 1976; 70:261-286.

13. Megyesi K, Kahn CR, Roth J, Gorden P, Neville DM, Jr. Radioreceptor assay of plasma NSILA-s in man: Basal and stimulated levels in normal and pathological states. In: Pecile A, Muller EE, eds. Growth hormone and related peptides, Proceedings of the Third International Symposium. Amsterdam: Excerpta Medica, 1976:127-140.
14. De Meyts P, Kahn CR, Roth J, Bar RS. Hormonal regulation of the affinity and concentration of hormone receptors in target cells. *Metabolism* 1976;25(Suppl. 1):1365-1370.
15. Roth J, Kahn CR, De Meyts P, Gorden P. Biologically relevant regulation of the affinity and concentration of insulin receptors. In: Clark JH, Klee W, Levitzki A, Wolff J, eds. Hormone and antihormone action at the target cell. Berlin: Abakon Verlagsgesellschaft, 1976:87-94.
16. Kahn CR, Bar RS, Kosmakos FC, Roth J. Regulation of insulin receptors by in vivo and in cell culture. In: James, VHT, ed. *Endocrinology Vol. 1: Proceedings of the V International Congress of Endocrinology*, Hamburg, July 18-23, 1976. Amsterdam-Oxford: Excerpta Medica, 1977:486-491.
17. Gorden P, Kahn CR, Flier JS, Bar RS, Roth J. Insulin receptor deficiency. In: James, VHT, ed. *Endocrinology Vol. II: Proceedings of the V International Congress of Endocrinology*, Hamburg, July 18-23, 1976. Amsterdam-Oxford: Excerpta Medica, 1977:329-335.
18. Megyesi K, Kahn CR, Roth J, Gorden P. Physiology of non-suppressible insulin-like activity. In: James, VHT, ed. *Endocrinology Vol. II: Proceedings of the V International Congress of Endocrinology*, Hamburg, July 18-23, 1976, Amsterdam-Oxford: Excerpta Medica, 1977:173-177.
19. Kahn CR, De Meyts P, Ginsberg BH, Roth J. Cooperative properties of hormone receptors. In: Bonfils S, Fromageot P, Rosselin G, eds. *Hormonal receptors in digestive tract physiology*. North-Holland Publishing Corp., 1977:103-112.
20. Kahn CR, Flier JS, Jarrett DB, Roth J. Use of anti-receptor antibodies as probes of receptor structure and function. In: Bonfils S, Fromageot P, Rosselin G, eds. *Hormonal receptors in digestive tract physiology*. North-Holland Publishing Corp., 1977:69-78.
21. Roth J, Neville DM, Jr., Kahn CR, Gorden P. Hormone resistance and hormone sensitivity. *N Eng J Med*. 1977; 269:277-278.
22. Roth J, Kahn CR, De Meyts P, Gorden P, Neville DM, Jr. Receptors for insulin and other peptide hormones in disease states. In: Bajaj JS, ed. *Insulin and metabolism*. Amsterdam: Excerpta Medica. 1977:73-80.
23. Kahn CR. The role of insulin receptors in obesity and diabetes. *Drug Therapy*. 1978; 8:107-118.
24. Kahn CR. Hypoglycemia. In: Melmon KL, Morrelli HF, eds. *Clinical pharmacology: Basic principles in therapeutics*. MacMillan Publishing Co., 1978:536-546.

25. Gorden P, Kahn CR, Flier JS, Bar RS, Roth J. Antibodies to insulin receptor: Probes of receptor structure and function. *Proc Fed Eur Biochem Soc.* 1978:239-247.
26. Muggeo M, Bar RS, Roth J, Harrison LC, De Meyts P, Kahn CR. Pathophysiology of insulin receptors in man. *Proceedings, Covegno Europeo sur Metabolisano*, 1978:101-118.
27. Muggeo M, Bar RS, Roth J, Kahn CR, Gorden P. Insulin receptors: Biologically relevant regulation of concentration and affinity. In: Miescher PA, ed. *Menarini series on immunopathy: First symposium on organ specific autoimmunity*. Basel: Schwabe and Co. 1978:149-159.
28. Harrison LC, Flier JS, Kahn CR, Roth J. Autoantibodies to the insulin receptor: Clinical and molecular aspects. In: Rose NR, Bigazzi PE, Warner NL, eds. *Genetic control of autoimmune disease*. New York: Elsevier-North-Holland Publ. Co., 1978:61-76.
29. Kahn CR, Baird KL. The role of receptor aggregation in insulin action. In: DeLisi C, Blumenthal R, eds. *Physical-chemical aspects of cell surface events in cellular regulation*. New York: Elsevier-North-Holland Publ. Co., 1978:119-127.
30. Bar RS, Harrison LC, Muggeo M, Gorden P, Kahn CR, Roth J. Regulation of insulin receptors in normal and abnormal physiology in humans. *Adv Intern Med.* 1979; 24:23-46.
31. Roth J, Lesniak MA, Megyesi K, Kahn CR. Hormone receptors, human disease and disorders in receptor design. *Cold Spring Harbor Conference on cell proliferation.* 1979; 6:167-186.
32. Kahn CR, Bar RS, Flier JS, Gorden P, Roth J. Insulin receptors in obesity and diabetes. In: Graves GD, ed. *Early detection of potential diabetics: The problems and the promise*. New York: Raven Press, 1979:225-250.
33. Kahn CR. Autoantibodies to the insulin receptor: Clinical and molecular aspects. *Fed Proc.* 1979; 38:2607-2609.
34. Kahn CR. The role of insulin receptors and receptor antibodies in states of altered insulin action. *J Exp Biol.* 1979; 162:13-21.
35. Kahn CR. The role of insulin receptors in states of altered insulin action. In: Waldhausl WK, ed. *Proceedings of the 10th meeting of the International Diabetes Federation*, Sept. 9-14, 1979. Vienna: Excerpta Medica (ICS #500). 1979:81-87.
36. Kahn CR, Muggeo M, Flier JS, Harrison LC. Autoantibodies to the insulin receptor in insulin resistant diabetes. In: Irvine WJ, ed. *Immunology of diabetes mellitus*, Edinburgh: Teviot Sci Publ Co. 1980:205-218.
37. Muggeo M, Kahn CR, Bar RS, Flier F, Valerio A, Roth J, Crepaldi G. The insulin receptors in hypoglycemia. In: Andreani D, Lefebvre PJ, Marks U, eds. *Current views on*

- hypoglycemia and glucagon. London: Academic Press. 1980:305-320.
38. Harrison LC, Kahn CR. Autoantibodies to the insulin receptor: Clinical significance and experimental applications. *Prog Clin Immunol.* 1980; 4:107-126.
  39. Kahn CR, Harrison LC. Insulin receptor autoantibodies. In: Randle PJ, Steiner DF, Whelan WJ, eds. *Carbohydrate metabolism and its disorders, Volume IV.* London: Academic Press, 1980:279-330.
  40. Rechler MM, Schilling EE, King GL, Fraioli R, Rosenberg AM, Higa OZ, Podskalny JM, Grunfeld C, Nissley SP, Kahn CR. Receptors for insulin and insulin-like growth factors in disease. In: Pepeu G, Kuhar MJ, Ennon SJ, eds. *Receptors for neurotransmitters and peptide hormones.* New York: Raven Press, 1980:489-497.
  41. Kahn CR, Harrison LC, Flier JS, Muggeo M, Van Obberghen E, Grunfeld C, Karlsson FA, King GL, Roth J. Antibodies to the insulin receptor and insulin-resistant diabetes. In: Pinchera A, Doniach D, Fenzi GF, Baschieri L, eds. *Autoimmune aspects of endocrine disorders.* London: Academic Press, 1980:275-289.
  42. Kahn CR, Flier JS. Immunologic aspects of endocrine disease. In: Parker CW. ed. *Clinical immunology.* Philadelphia: WB Saunders, 1980:815-866.
  43. Kahn CR. The role of insulin receptors in insulin resistant states. *Metabolism* 1980; 29:455-467.
  44. Kahn CR, Grunfeld C, King GL, Van Obberghen E, Baird KL. Insulin receptors, receptor antibodies and the mechanism of insulin action. In: Brandenburg D, Wollmer A, eds. *Insulin: Chemistry, structure and function of insulin and related hormones.* Berlin: de Gruyter, 1980:483-494.
  45. Rosenthal AS, Blake JT, Kahn CR, Mann D, Galloway J. Genetic control of the immune response to insulin: A clinical study of adverse immunological reactions to insulin. In: Brandenburg D, Wollmer A, eds. *Insulin: Chemistry, structure and function of insulin and related hormones.* Berlin: de Gruyter, 1980:585-592.
  46. Harrison LC, Van Obberghen E, Grunfeld C, King GL, Kahn CR. Modulation of the insulin receptor by insulin receptor autoantibodies. In: Kobler, Cohen, eds. *Membranes, receptors and the immune response.* New York: Alan Liss, 1980:109-126.
  47. Van Obberghen E, Kahn CR. Anticorps diriges contre le recepteur de l'insuline et diabete insulino-resistant. In: *Journees Annuelle de Diabetologie de l'Hotel-Dieu.* Paris: Flammarion Medicine-Sciences, 1980:283-296.
  48. Kahn CR, Harrison LC. Insulin receptor autoantibodies. In: Randle PJ, Steiner DF, Whelan WJ, eds. *Carbohydrate metabolism and its disorders, Vol. III.* London: Academic Press, 1981:279-330.
  49. Mann DL, Rosenthal AS, Kahn CR, Johnson AH, Mendell N. A study of HLA alloantigen frequencies in insulin allergic and non-allergic diabetes. In: Keck K, Erb P, eds. *Basic*

- and clinical aspects of immunity to insulin. Berlin and New York: Walter de Gruyter, 1981:275-284.
50. King GL, Kahn CR. Non-parallel evolution of metabolic and growth-promoting functions of insulin. *Nature*. 1981; 292:644-646.
  51. Kahn CR, Baird KL, Flier JS, Grunfeld C, Harmon JT, Harrison LC, Karlsson FA, Kasuga M, King GL, Land UC, Podskalny JM, Van Obberghen E. Insulin receptors, receptor antibodies and the mechanism of insulin action. *Recent Prog Horm Res*. 1981; 37:477-538.
  52. Kahn CR, Van Obberghen E, King GL, Baird KL, Grunfeld C. Antibodies to insulin receptors as probes of insulin action. In: Andreani D, De Pirro R, Lauro R, Olefsky J, Roth J, eds. *Current views on insulin receptors*. London: Academic Press, 1981:261-273.
  53. Van Obberghen E, Kahn CR. Autoantibodies to insulin receptors. *Mol Cell Endocrinol*. 1981; 22:277-293.
  54. Danho W, Bullesbach EE, Gattner HG, King GL, Kahn CR. Syntheses and biological properties of "hybrids" between human insulin and insulin-like growth factor I. In: Rich DH, Cross E, eds. *Peptides: Synthesis, structure and function*. Pierce Chemical Co. 1981:113-122.
  55. Kahn CR. Insulin receptors and syndromes of insulin resistance. *Diabetes Care*. 1982; 5:98-101.
  56. Kahn CR, Kasuga M, King GL, Grunfeld C. Autoantibodies to insulin receptors in man: Immunological determinants and mechanism of action. In: *Receptors, receptor antibodies and disease (Ciba Symposium No. 90)*. London: Pitman Medical Publ. Co., 1982:91-104.
  57. Kahn CR. Autoimmunity and the etiology of insulin dependent diabetes mellitus. *Nature*. 1982; 299:15-16.
  58. Fehlmann M, Crettaz M, Kahn CR, Freychet P. Hormonal regulation of Na<sup>+</sup> dependent transport in hepatocytes and hepatoma cells. In: Boynton AL, McKeegan WL, Whitfield JF, eds. *Cell proliferation and cancer*. New York: Academic Press, 1982:163-174.
  59. Kahn CR. Treatment of insulinoma and non-islet tumors producing hypoglycemia. In: Krieger DT, Bardin CW, eds. *Current therapy in endocrinology*. Philadelphia: BC Decker, 1983:222-227.
  60. Kahn CR. Insulin allergy and insulin resistance. In: Lichtenstein LM, Fauci AS, eds. *Current therapy in allergy and immunology*. Toronto: Decker and Mosby Publishers, 1983:315-318.
  61. Kahn CR, Hedo J, Kasuga M. Structure, biosynthesis and phosphorylation of the insulin receptor. In: Imura H, Kuzuya H, eds. *Hormone receptor and receptor disease. Proceedings of the International Symposium on Hormone Receptors and Receptor Disease*. Amsterdam-Oxford-Princeton: Excerpta Medica, 1983:3-11.

62. Kahn CR, Maron R. Immunology of the insulin receptor. In: Andreani D, Di Mario U, eds. Immunology in diabetes. Edinburgh and London: Academic Press, 1984:209-219.
63. Rosenthal AS, Mann D, Kahn CR. Genetic control of the immune response to insulin in man and experimental animals. In: Gupta S, ed, Immunology of diabetes man and animals. New York: Plenum Publishing Co., 1984:51-71.
64. King GL, Kahn CR. The growth-promoting effects of insulin. In: Guroff G, Ed. Growth and maturation factors. New York: Wiley and Sons, Inc., 1984:224-265.
65. Kasuga M, Hedo JA, Kahn CR. Antibodies to the insulin receptor: Studies of receptor structure and function. In: Litwack G, ed. Biochemical actions of hormones, Vol XI. New York: Academic Press, 1984:127-162.
66. Crettaz M. Kahn CR. Study of insulin receptors in intact cells using specific antibodies. In: Larner J, Pohl S, eds. Methods in diabetes research. New York: J Wiley Publishers, 1984:30-43.
67. Kahn CR. Acanthosis nigricans: A marker for states of cellular resistance to insulin. *Clinical Diabetes* 1984; 2:112-113.
68. Kasuga M, Hedo JA, Kahn CR, Crettaz M, Ezaki O, Kadowaki T. Structure and biosynthesis of the insulin receptor. In: Labrie F, Proulx L, ed. *Endocrinology*. Elsevier Science Publishers, 1984:339-343.
69. Kahn CR, Crettaz M, Grigorescu F, Takayama S, Ganda OP, Flier JS. The role of insulin receptor kinase activity in insulin action: Implications from insulin resistant states. In: Labrie F, Proulx L, ed. *Endocrinology*. Elsevier Science Publishers, 1984:249-256.
70. Kahn CR. Insulin receptors. In: Alberti KGMM, Krall LP, ed. *The Diabetes Annual*. Amsterdam-New York-Oxford: Elsevier. 1985:446-462.
71. Hedo JA, Kahn CR. Radioactive labeling and turnover studies of the insulin receptor subunits. In: Birnbaumer L, O'Malley B, eds. *Methods in Enzymology*. New York: Academic Press. 1985:593-609.
72. Kasuga M, White MF, Kahn CR. Phosphorylation of the insulin receptor in cultured hepatoma cells and a solubilized system. In: Birnbaumer L, O'Malley B, eds. New York: Academic Press. 1985:609-621.
73. Kahn CR. Insulin allergy and insulin resistance. In: Kreiger DT, Bardin CW, eds. *Current Therapy in Endocrinology and Metabolism*. Philadelphia: BC Decker Inc. 1985:281-283.
74. Kahn CR, White MF, Grigorescu F, Takayama S, Haring HU, Crettaz M. The insulin receptor protein kinase. In: Czech M, ed. *Molecular basis of insulin action*. New York: Plenum Press. 1985:67-93.
75. Crettaz M, Kahn CR. Insulin receptors and the molecular mechanism of insulin action.

- Diabetes/Metabolism Review 1985; 1:5-32.
76. Kahn CR. The insulin receptor and insulin: A lock and key to understanding diabetic syndromes. *Diabetes Countdown* 1985:9-11.
  77. Kahn CR, Kasuga M, King GL. Antibodies to insulin receptors as probes of receptor structure and function. In: Posner B, ed. *Polypeptide Hormone Receptors*. New York: Marcel-Decker, 1985:113-135.
  78. King GL, Kahn CR. Effect of insulin on growth in vivo and cell in culture. In: Boynton AL, Leffert HL, eds. *Cell Proliferation: Recent Advances*. Academic Press, Inc. 1985:201-249.
  79. Podskalny JM, Kahn CR. Cultured fibroblasts: Studies of insulin binding and action. In: DiPirro R, et al. *Insulin Receptors*. Acta Medica, 1985:117-128.
  80. White MF, Werth DK, Pastan I, Kahn CR. Phosphorylation of solubilized insulin receptor between other rous sarcoma virus, pp60<sup>src</sup> (Czech M, Kahn CR, eds.) Alan R. Liss, Inc. New York, Vol. 23, 1985:55-69.
  81. Herzberg VL, Grigorescu F, Edge ASB, Spiro RG, Kahn CR. Characterization of insulin receptor carbohydrate by comparison of chemical and enzymatic deglycosylation. *Biochem Biophys Res Commun* 1985; 129:789-796.
  82. Kahn CR. Insulin Resistance: A common feature of diabetes mellitus. *N Engl J Med*. 1986; 315:252-254.
  83. Eastman RC, Rittmaster RS and Kahn CR. Hypoglycemia. In: Kohler PO, ed. *Clinical Endocrinology*. New York: John Wiley and Sons, Inc., 1986:465-490.
  84. White MF, Kahn CR. The insulin receptor and tyrosine phosphorylation. In: Krebs EG, Boyer PD, eds. *The Enzymes*, Volume XVII. New York: Academic Press, Inc., 1986:257-310.
  85. Kahn CR, Grigorescu F, Takayama S, White MF. The insulin receptor as a protein kinase. In: Gotto AM, O'Malley B, eds. *Role of Receptors in Biology and Medicine*. New York: Raven Press, 1986:137-160.
  86. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of Type I diabetes mellitus and its complications In: Flier JS, Underhill LH, eds. *Seminars in Medicine of the Beth Israel Hospital*. *N Eng J Med* 1987; 317:1390-1398.
  87. Karasik A, Kahn CR. Antibodies to the insulin receptor in study of receptor structure and function. In: Drachman DB, ed. *Myasthenia Gravis: Biology and Treatment*, Vol. 505. New York: Academy Science. 1987:301-311.
  88. Kahn CR, Warram JH, Krolewski AS, Takayama S, Soeldner JS. Insulin resistance and non-insulin dependent diabetes mellitus. In: Grill V, Efendic S, eds. *Pathogenesis of Non-Insulin Dependent Diabetes Mellitus*. New York: Raven Press, 1988:227-239.

89. Kahn CR. The role of tyrosine phosphorylation in insulin action. In: Henry HL, Norman AW, eds. Contributions to Cellular and Molecular Endocrinology. Riverside: Publisher Proceedings of the Tenth Annual University of California Riverside-Nichols Institute Symposium on Cellular and Molecular Endocrinology, 1988:60-68.
90. White MF, Kahn CR. Structural and functional studies of the insulin receptor kinase. In: Harrison LC, Kahn CR, eds. Vol. eds. Insulin receptors. Part A: Methods for the study of structure and function. Receptor Biochemistry and Methodology, Vol. 12A. New York: Alan R Liss, Inc., 1988:125-145.
91. Goldstein BJ, Kahn CR. Insulin allergy and insulin resistance current therapy in allergy, immunology and rheumatology. In: Lichtenstein LM, ed. Third Edition of Current Therapy in Allergy, Immunology and Rheumatology. Lewiston, New York: BC Decker, Inc., 1988:327-330.
92. Kahn CR, Harrison LC, eds. Insulin receptors. Part A. Methods for the study of structure and function. Receptor Biochemistry and Methodology. Vol. 12 A. New York: Alan R Liss, Inc. 1988.
93. Kahn CR, Harrison LC, eds. Insulin receptors. Part B. Clinical assessment, biological responses and comparison to the IGF-I receptor. Receptor Biochemistry and Methodology. Vol. 12B. New York: Alan R Liss, Inc. 1988.
94. Kahn CR, Reddy SSK, Shoelson SE, Goren HJ, White MF. Regulation of the insulin receptor by multi-site phosphorylation. IN: (H.J. Goren, M.D. Hollenberg, D.A.K. Roncari, eds.) Insulin Action and Diabetes. Raven Press: New York. 1988:43-53.
95. Kahn CR. Membrane receptors for peptide hormones. IN: (L.J. DeGroot, ed.) Endocrinology, Second Edition, Volume 1. W.B. Saunders, Co.: Philadelphia, PA. 1988:40-57.
96. Gross DJ, Halban PA, Weir GC, Kahn CR, Villa-Komaroff L. In: Hanahan D, McDevitt HO, Cahill, Jr., George F, eds. Current Communications in Molecular Biology: Perspectives on the molecular biology and immunology of the pancreatic  $\beta$ -cell. Mutations of proinsulin: Effects on secretion and processing. Proceedings of the Cold Spring Harbor Meeting, October 1988. 1989:43-48.
97. Cahill, Jr., George F, Kahn CR. In: Hanahan D, McDevitt HO, Cahill, Jr., George F, eds. Current Communications in Molecular Biology: Perspectives on the molecular biology and immunology of the pancreatic  $\beta$  cell. Pancreatic islet cells in diabetes mellitus: A clinical perspective. Proceedings of the Cold Spring Harbor Meeting, October 1988. 1989:3-16.
98. Kahn CR, Goldstein BJ, Shoelson SE. Mechanisms of insulin receptor activation and biosynthesis. In: Imura H, Shizume K, Yoshida S, eds. Proceedings of the 8th International Congress of Endocrinology, Kyoto, Japan, July 1988, Progress in Endocrinology 1988. Amsterdam-New York-Oxford: Excerpta Medica, 1988:371-376

99. Shoelson SE, Kahn CR. Phosphorylation, the insulin receptor, and insulin action. In: Draznin B, Melmed S, LeRoith D, eds. *Molecular and Cellular Biology of Diabetes Mellitus, Volume II: Insulin Secretion*. New York: Alan R. Liss, Inc., 1989:23-33.
100. Kahn CR. Type II diabetes mellitus. In: Kelley WN, ed. *Textbook of Internal Medicine*. Philadelphia: J. B. Lippincott Co., 1989:2216-2222.
101. Kahn CR. Perverted Priorities. The physician/scientist as spokesman and salesman for biomedical research. Presidential Address: American Society for Clinical Investigation Annual Meeting, Washington, D.C. *J Clin Invest* 1989; 84:723-727.
102. Eastman RC, Kahn CR. Hypoglycemia. In: Moore WT, Eastman RC, eds. *Diagnostic Endocrinology*. Philadelphia: B.C. Decker, Inc., 1990:183-199.
103. Kahn CR, Catanese VM. Secondary forms of diabetes. In: Becker KL, ed. *Principles and Practice of Endocrinology and Metabolism*. Philadelphia: J.B. Lippincott, Co., 1990:1087-1093, 1255-1256.
104. Rothenberg PL, White MF, Kahn CR. The insulin receptor tyrosine kinase. In: Cuatrecasas P, Jacobs S, eds. *Handbook of Experimental Pharmacology, Vol. 92, Insulin*. Heidelberg, Germany: Springer-Verlag, 1990:209-236.
105. Rothenberg PL, Kahn CR. The role of covalent and non-covalent mechanisms in insulin receptor action. IN: Vanderhoek JY, ed. *Biology of Cellular Transducing Signals (Proceedings of the Ninth International Washington Spring Symposium)*. New York: Plenum Press, 1990:29-38.
106. Kahn CR, Goldstein BJ, Reddy SSK. Hereditary and acquired syndromes of insulin resistance. IN: Pickup JC, Williams G, eds. *Textbook of Diabetes. Volume 1*. London: Blackwell Scientific Publications, 1990:276-285.
107. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. IN: Klimes I, Howard BV, Kahn CR, eds. *Insulin and the cell membrane*. New York: Harwood Academic Publishers. 1990:3-18.
108. Goldstein BJ, Meyerovitch J, Zhang WR, Backer JM, Csermely P, Hashimoto N, Kahn CR. Hepatic protein-tyrosine phosphatases and their regulation in diabetes. *Advances in Protein Phosphatases*. 1991; 6:1-17.
109. Kahn CR, Smith RJ, Chin WW. Mechanism of action of hormones that act at the cell surface. In: *Williams Textbook of Endocrinology*, ed. Wilson JD, Foster DW. W.B. Saunders: Philadelphia, 1991:91-134.
110. Muller-Wieland D, White MF, Behnke B, Gebhardt A, Neumann S, Krone W, Kahn CR. Pertussis toxin inhibits autophosphorylation of the insulin receptor kinase. *Biochem Biophys Res Commun* 1991; 181:1479-1485.
111. Backer JM, Schroeder GG, Cahill DA, Ullrich A, Siddle K, White MF, Kahn CR. The

- cytoplasmic juxtamembrane region of the insulin receptor: A critical role in ATP binding, endogenous substrate phosphorylation, and insulin stimulated bioeffects in CHO cells. *Biochemistry* 1991; 30:6366-6372.
112. Kahn CR, Saad MJA. Alterations in insulin receptor and substrate phosphorylation in hypertensive rats. *J Amer Soc Nephropathy* 1992; 3:S69-S77.
  113. Goldstein BJ, Kahn CR. Insulin receptors in normal and disease states. IN: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. *International Textbook of Diabetes Mellitus*, New York: John Wiley and Sons Ltd, 1992:357-383.
  114. Kahn CR, Araki E, Saad MJ, Folli F, Zoppini G, Huertas P. Molecular aspects of insulin action, insulin resistance, and their relationship to atherosclerosis. In: *Atherosclerosis Reviews*, Vol. 25. Weber PC, Leaf A, eds. Raven Press, Ltd.: New York, New York. 1993:209-224.
  115. Goldfine AB, Kahn CR. Molecular determinants of insulin action. *J Diab Comp* 1993; 7:92-105.
  116. Kahn CR, White MF, Shoelson SE, Backer JM, Araki E, Cheatham B, Csermely P, Folli F, Goldstein BJ, Huertas P, Rothenberg PL, Saad MJA, Siddle K, Sun XJ, Wilden PA, Yamada K, Kahn SA. The insulin receptor and its substrate: Molecular determinants of early events in insulin action. *Recent Progress in Hormone Research* Vol. 48. Academic Press, 1993:291-339.
  117. Kahn CR, Folli F. Molecular determinants of insulin action. *Horm Res* 1993; 39:93-101.
  118. Kasuga M, Karlsson FA, Kahn CR. Identification of the insulin receptor tyrosine kinase activity. *Current Contents: Life Sciences* 1993; 36:9. (Citation Classics - Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000 dalton subunit of its own receptor. *Science* 1982; 215:185-187).
  119. Kahn CR, Araki E, Saad MJ, Folli F, Zoppini G, Huertas P. Molecular aspects of insulin action, insulin resistance, and their relationship to atherosclerosis. In: Weber PC, Leaf A, eds. *Atherosclerosis Reviews*, Volume 25. New York: Raven Press, Ltd. 1993:209-227.
  120. White MF, Kahn CR. Mechanisms of insulin action. In: Moller DE, ed. *Insulin Resistance*. Chichester, NY: John Wiley & Sons, Ltd., 1993:9-47.
  121. Kahn CR, and Schechter Y. Oral hypoglycemic agents. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. *The pharmacologic basis of therapeutics*. NY: McGraw-Hill, 1485.
  122. White MF, Kahn CR. Molecular aspects of insulin action. In: Kahn CR, Weir GC, eds. *Joslin's Diabetes Mellitus*, 13th Edition. Philadelphia: Lea & Febiger, Inc. 1994:139-162.
  123. White MF, Kahn CR. The insulin signaling system. *J Biol Chem* 1994; 269:1-4.

124. Goldfine AB, Kahn CR. Insulin allergy and insulin resistance. In: Bardin CW, ed. *Current Therapy in Endocrinology and Metabolism*. St. Louis: Mosby-Year Book, Inc. 1994:461-464.
125. Kahn CR, Reynet C. Identification of diabetes-related genes by subtraction cloning. In: Draznin B, LeRoith D, eds. *Molecular Biology of Diabetes, Volume II: Insulin Action, Effects on Gene Expression and Regulation, and Glucose Transport*. Totowa, NJ: Humana Press, Inc. 1994:51-78.
126. Araki E, Kahn CR, Shichiri M. Structure and regulation of the insulin receptor substrate-1 (IRS-1). In: Sakamoto N, Alberti KGMM, Hotta N, eds. *Pathogenesis and Treatment of NIDDM and its Related Problems*. Elsevier Science B.V. 1994:243-249.
127. Araki E, Kahn CR, Shichiri M. Characterization of the IRS-1 (insulin receptor substrate-1) gene and its promoter. *Nippon Rinsho*. 1994; 52:2659-2664.
128. Kahn CR. Diabetes and the endocrine pancreas. Editorial overview. *Curr Opin Endocrinol Diabetes* 1994; 1:219-220.
129. Kahn CR. Book Review: *Life and Death of the Beta Cell*. *TEM* 1995; 6:254-255. (Molecular Biology of Diabetes. I. Autoimmunity and Genetics; Insulin Synthesis and Secretion. Edited by Boris Draznin and Derek LeRoith. Totowa, NJ: Humana Press, 1994.)
130. Gammeltoft S, Kahn CR. Hormone signaling via membrane receptors. In: DeGroot LJ, LeRoith D, eds. *Endocrinology, Third Edition*. Philadelphia: W.B. Saunders Company, 1995:17-65.
131. Kahn CR, White MF. The molecular mechanism of insulin action. In: DeGroot L, LeRoith D, eds. *Endocrinology, 3rd Edition*. Philadelphia: W.B. Saunders Company, 1995:1373-1388.
132. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. *Endocrine Reviews* 1995; 16:117-142.
133. Kahn CR. The insulin receptor, insulin action and the mechanisms of insulin resistance in diabetes and atherosclerosis. In: Schwartz CJ, Born GVR, eds. *New Horizons in Diabetes Mellitus and Cardiovascular Disease*. London: Science Press (Current Science), 1995:46-56.
134. Kahn CR. Glucose homeostasis and insulin action. In: Becker KL, ed. *Principles and Practice of Endocrinology and Metabolism, 2nd edition*. Philadelphia: L.B. Lippincott, 1995:1198-1202.
135. Kahn CR. Etiology and pathogenesis of Type II diabetes mellitus and related disorders. In: Becker KL, ed. *Principles and Practice of Endocrinology and Metabolism, 2nd edition*. Philadelphia: L.B. Lippincott, 1995:1210-1216.
136. Catanese VM, Kahn CR. Secondary forms of diabetes mellitus. In: Becker KL, ed.

- Principles and Practice of Endocrinology and Metabolism, 2nd edition. Philadelphia: L.B. Lippincott, 1995:1220-1228.
137. Kahn CR. An introduction to Type II diabetes. (Commentary) *Curr Opin Endocrinol Diab.* 1995; 2:283-284.
  138. Kahn CR. Causes of insulin resistance. *Nature* 1995; 373:384-385.
  139. Kahn CR, ed. Diabetes and the endocrine pancreas: I. *Curr Opin Endocrinol Metab.* 1995; 2:3-77, 1068-3097.
  140. Kahn CR, ed. Diabetes and the endocrine pancreas: II. *Curr Opin Endocrinol Metab.* 1995; 2:283-363, 1068-3097.
  141. Kahn CR, section ed. Disorders of fuel metabolism. In: Becker KL, ed. *Principles and Practice in Endocrinology and Metabolism*, 2nd edition. 1995:1148-1409.
  142. Kahn CR, Vicent D, Doria A. Genetics of non-insulin-dependent (Type II) diabetes mellitus. *Annu Rev Med.* 1996; 47:509-531.
  143. Kahn CR. The role of obesity in diabetes mellitus: Editorial Overview. *Curr Opin Endocrinol Metab* 1996; 3:1-2.
  144. Cheatham B, Kahn CR. The biochemistry of insulin action. In: LeRoith D, Taylor SI, Olefsky JM, eds. *Diabetes Mellitus: A Fundamental and Clinical Text*. Philadelphia: J.P. Lippincott Company, 1996:139-147.
  145. Kahn CR. New concepts in the pathogenesis of diabetes mellitus. In: Schrier RW, Baxter JD, Abboud F, Fauci AS, eds. *Advances in Internal Medicine*, Vol. 41. St. Louis: Mosby-Year Book, Inc., 1996:285-321.
  146. Gammeltoft S, Kahn CR. Functional domains of tyrosine kinase-linked receptors. In: Foreman JC, Johansen T, eds. *Textbook of Receptor Pharmacology*. Boca Raton, FL: CRC Press, 1996:101-117.
  147. Folli F, Saad MJA, Kahn CR. The insulin receptors/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. *ACTA Diabetologica* 1996; 33:185-192.
  148. Patti ME, Kahn CR. Lessons from transgenic and knockout animals about NIDDM. *Trends Endocrinol Metab* 1996; 7:311-319.
  149. Folli F, Ghidella S, Bonfanti L, Kahn CR, Merighi A. The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. *Mol Neurobiology* 1996; 13:155-183.
  150. Maratos-Flier E, Goldstein BJ, Kahn CR. The insulin receptor and postreceptor mechanisms. In: Pickup JC, Williams G, eds. *Textbook of Diabetes*, Second Edition. Oxford: Blackwell Science, Inc. 1997:10.1-10.22.

151. Kahn CR. Insulin receptors and insulin signaling in normal and disease states. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, Eds. International Textbook of Diabetes Mellitus, Second Edition. 1997:437-467.
152. Patti ME, Kahn CR. Transgenic animal models: Insights into the pathophysiology of NIDDM. *Diab Rev* 1997; 5:149-164.
153. Heesom HJ, Harbeck M, Kahn CR, Denton RM. Insulin action on metabolism. *Diabetologia* 1997; 40:B3-B9.
154. Kahn CR, Smith RJ, Chin WW. Mechanisms of action of hormones that act at the cell surface. Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. *Williams Textbook of Endocrinology*, 9<sup>th</sup> Edition. WB Saunders, Co.: Philadelphia, PA. 1998:95-143.
155. Kahn CR. Tribute: Rachmiel Levine, M.D. 1910-1998. *Diabetes*. 1998; 47:991-992.
156. Patti ME, Kahn. The insulin receptor – a critical link in glucose homeostasis and insulin action. *J Basic Clin Phys Pharmacol*. 1998; 9:89-109.
157. Emkey R, Kahn CR. Molecular aspects of insulin signaling. In: Jefferson LS, Cherrington AD, eds. *Handbook of Physiology*. New York: Oxford University Press, 1999.
158. Kahn CR. Diabetes: A strategic plan for the 21<sup>st</sup> Century. *Diabetes Metab Res Rev*. 1999; 15:152-155 (an interview).
159. Kahn CR. Insulin signaling and the molecular mechanisms of insulin resistance. In: Imura H, Kasuga M, Nakao K, ed. *Common Disease- Genetic and Pathogenetic Aspects of Multifactorial Diseases*. Uehara Memorial Foundation Symposium-1999. New York: Elsevier; 1999:61-77.
160. Kahn CR. Signalisation de l'insuline et mecanismes moleculaires de l'insulinoreistance. *flammarion medecine-sciences. Journees Annu. de Diabetologie Hotel Dieu* 1999:124-141.
161. Bruning JC, Kahn CR, Krone W, Muller-Wieland D. [Conditional mutagenesis—second generation knockout mice as models for internal diseases]. *Med Klin*. 1999; 94:564-9. Article in German.
162. Kahn CR. The pathogenesis of type 2 non-insulin-dependent diabetes. In Korenman SG, ed. *Atlas of Clinical Endocrinology, Volume 2: Diabetes*. Philadelphia: Current Medicine, Inc. 2000:71-82.
163. Kahn CR. Citation for the 2000 Roy O. Greep Award Lecture of The Endocrine Society to Dr. Christin Carter-Su. *Endocr Rev*. 2000; 21:452-453.
164. Kulkarni, RN, Michael, MD, Kahn, CR. Tissue-Specific knockouts of the insulin receptor tyrosine kinase. *Genetic Manipulation of Receptor Expression and Function* (ed. D. Accili). Wiley Publ. 2000; Chapter 8:129-154.

165. Kahn CR, Bruning JC, Michael MD, Kulkarni RN. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. *J Pediatr Endocrinol Metab.* 2000;13 Suppl 6:1377-84.
166. Kulkarni RN, Kahn CR. Genetic models of insulin resistance: alterations in b-cell biology. In: (J.F. Habener, M. Hussain, eds) *Molecular Basis of Pancreas Development and Function.* Kluwer Academic Publishers: Norwell, MA. 2001; pp.299-323.
167. Kulkarni, RN, Michael, MD, Kahn, CR. Tissue-Specific knockouts of the insulin receptor tyrosine kinase. *Genetic Manipulation of Receptor Expression and Function.* 2000; Chapter 8: 129-154.
168. Fruman DA, Mauvais-Jarvis F., Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC, Hypoglycaemia, liver necrosis and prenatal death in mice lacking all isoform phosphoinositide 3-kinase p85 alpha. *Nat Genet.* 2000 Nov;26(3):379-82.
169. Michael MD, Kahn CR. Defects in early insulin signaling skeletal muscle. In: (Zierath JR, Wallberg-Henriksson H eds) *Muscle Metabolism.* Taylor & Francis: New York, NY. 2002; pp.37-66.
170. Kahn CR, Fisher SJ. Physiologic mechanisms in Homeostatic control of glucose. *Comprehensive Clinical Endocrinology Third Edition.* 2002; Chapter 19: 239-254.
171. Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. *Annu Rev Physiol* 2003;65:313-32.
172. Kahn, CR. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice. *Transactions of the American Clinical and Climatological Association, The Gordon Wilson Lecture, 2003 Vol. 114.*
173. Kahn CR. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. *Exp Diabetes Res.* 2003 Jul-Sep;4(3):169-82.
174. Almind K, Accili D, Kahn CR. Knockout mice as a tool to the understanding of diabetes mellitus. In LeRoith D, Taylor SI, Olefsky ed. *Diabetes Mellitus: A Fundamental and Clinical Text 3<sup>rd</sup> Edition.* New York: Lippincott Williams & Wilkins 2004: 245-254.
175. Nandi A, Kitamura Y, Kahn CR, Accili D. Mouse models of insulin resistance. *Physiol Rev.* 2004 Apr;84(2):623-47.
176. Bouche C, Serdy S, Kahn CR, Goldfine AB. The cellular fate of glucose and its relevance in type 2 diabetes. *Endocr Rev.* 2004 Oct;25(5):807-30.
177. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. *Diabetes Metab Res Rev.* 2005 Jan-Feb;21(1):31-8.
178. Brown M, Flier J, Friedman J, Goldstein J, Kahn CR, Lifton R, O'Rahilly S, Spiegelman B. Cell Metabolism: Why, and why now? *Cell Metab.* 2005 Jan;1(1):3.

176. Katic M, Kahn CR. The role of insulin and IGF-1 signaling in longevity. *Cell Mol Life Sci.* 2005 Feb;62(3):320-43.
179. Taniguchi CM, Emanuelli B, Kahn CR. Critical Nodes in Signalling Pathways: A New Look at the Insulin Signalling Network. *Nature Reviews Molecular Cell Biology* 2006 Feb; 7(2):85-96.
180. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. *Annu Rev Physiol.* 2006;68:123-58.
181. Russell SJ, Kahn CR. Endocrine regulation of ageing. *Nat Rev Mol Cell Biol.* 2007 Sep;8(9):681-91.
182. Doria A, Patti Mary-Elizabeth, Kahn CR. The Emerging Genetic Architecture of Type 2 Diabetes. *Cell Metab.* 2008 Sep;8(3):186-200.
183. Kahn CR. The Origin of Fat: Can We Nip Obesity in the Vascular Bud? *Science.* 2008 Oct; 322: 542-543
184. Kahn CR. Health Care Reform – Need for Less Emotion and More Science. *J. Clin. Invest.* Epub 2009 Sept 11.
185. Bluher M, Stumvoll M, Kahn CR, Ristow M. High Baseline Vitamin C Levels Do Not Prevent a Positive Outcome of a Lifestyle Intervention. Response to Thamer et al. *Diab Care.* 2010 Jan; 33(1): e17. Epub 2009 Dec 30.

## **PATENTS**

- Kahn CR, White MF, Rothenberg PL. Isolated DNA encoding an insulin receptor substrate. US patent 5,260,200. 1993 Nov 3.
- Kahn CR, Reynet C. Diabetogene rad: A Type II diabetes specific gene. US patent 5,589,374. 1996 Dec 31.
- Kahn CR, White MF, Rothenberg PL. Insulin receptor substrate. US patent 5,621,075. 1997 Apr 15.
- Kahn CR, Reynet C. Diabetogene rad: A type II diabetes specific gene. US patent 5,891,430. 1999 Apr 6.